



维亚生物科技控股集团

VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

Stock Code: 1873

2025

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT



CONTENTS

ABOUT THE REPORT	2	4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION	59
CHAIRMAN'S STATEMENT	4	4.1. Supporting the Climate Actions	59
STATEMENT OF THE BOARD OF DIRECTORS	8	4.2. Energy Conservation and Emission Reduction Actions and Measures	67
ABOUT VIVA BIOTECH	9	4.2.1 Environmental Management Approach	67
SUSTAINABLE DEVELOPMENT STRATEGIES	15	4.2.2 CDMO Carbon Emission Reduction Roadmap	70
ESG Strategies and Goals	15	4.2.3 Green Operation	71
ESG Governance Structure	16	4.3. Waste Management	82
Communications with Stakeholders	18	4.3.1 Waste Gas Management	82
Materiality Assessment	19	4.3.2 Wastewater Management	84
1. COMMITMENT TO RESPONSIBLE CORPORATE GOVERNANCE	24	4.3.3 Hazardous Waste Management	86
1.1 Corporate Governance	24	4.3.4 Non-hazardous Waste Management	90
1.2 Business Ethics and Anti-corruption	27	4.4. Resource Management	93
1.3 Risk Management	29	4.4.1 Water Resource Management	93
2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION	32	4.4.2 Packaging Materials Management	94
2.1 R&D and Innovation	32	5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY	95
2.1.1 AIDD/CADD Platform	33	5.1. Employment Compliance and Employee Benefits	95
2.2 Intellectual Property Management	36	5.1.1 Employment Management	95
2.3 Quality Management	37	5.1.2 Employee Benefits and Care	99
2.3.1 Quality Management System	37	5.1.3 Employee Communication	101
2.3.2 Recall Procedures	38	5.2. Diversity, Equality and Inclusiveness	102
2.4 Animal Welfare and Rights	40	5.3. Occupational Health and Safety	103
2.4.1 Experimental Animal Management System	40	5.3.1 Safety Inspection	105
2.4.2 Animal Welfare Initiatives	41	5.3.2 Occupational Disease Prevention and Management	105
2.5 Protection of Clients' Rights and Interests	41	5.3.3 Equipment Safety and Hygiene Management	107
2.5.1 Customer Services	41	5.3.4 Occupational Health and Safety Training	108
2.5.2 Customer Complaint Mechanism	42	5.3.5 Emergency Response to Accidents	110
2.5.3 Privacy Protection and Information Security	43	5.4. Human Capital Development	111
2.6 Sustainable Supply Chain	45	5.4.1 Talent Attraction and Recruitment	111
2.6.1 Supplier Admission	46	5.4.2 Talent Retention and Promotion	113
2.6.2 Supplier Evaluation	49	5.4.3 Talent Motivation	114
3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPOWERMENT	50	5.4.4 Training and Talent Development	115
3.1. Responsible Investment	50	5.5. Community Responsibility and Contribution	119
3.2. Promoting Industry Cooperation	55	APPENDIX: HKEX ESG REPORTING CODE	122
3.3. Empowering Industry Development	58	CONTENT INDEX	

ABOUT THE REPORT

Overview of the Report

Viva Biotech Holdings (the “**Company**”, together with its subsidiaries, “**Viva Biotech**”, the “**Group**” or “**we/us**”) is pleased to release the seventh Environmental, Social and Governance Report (the “**Report**”) to society, in a bid to disclose the relevant performance of the Group in environmental, social and governance (“**ESG**”) aspects in the past year in a transparent and open manner and address the concerns and expectations of various stakeholders on the sustainable management of the Group.

Reporting Scope

The Report covers the performance of Viva Biotech Holdings and its subsidiaries in fulfilling corporate social responsibility in the ESG aspects within Mainland China, and a time span from January 1, 2025 to December 31, 2025 (the “**Reporting Period**” or the “**Year**”).

Basis of Preparation

The Group prepared the Report in accordance with the Environmental, Social and Governance Reporting Code (the “**ESG Code**”) as set out in Appendix C2 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”). The Report has complied with the “**Comply or Explain**” provisions contained in the ESG Code and followed the four reporting principles of materiality, quantitative, balance and consistency as the basis of preparation.

Reporting Principles

Materiality: Stakeholder communication and materiality assessment have been incorporated into the preparation of this ESG report as a basis for identifying material ESG issues.

Quantitative: The Report presents environmental and social key performance indicator(s) (“**KPI(s)**”) in the form of quantitative data, accompanied by explanations to illustrate their purposes and impacts. We also provide comparative data on environmental KPIs in the Report.

Balance: This ESG report follows the principle of balance and presents our ESG performance in an impartial manner.

Consistency: The methodologies for working out this ESG report are consistent with those adopted in the 2023 and 2024 ESG reports to ensure comparability of information.



ABOUT THE REPORT

Release Channel

The Report is available for inspection and download at the “HKEXnews” website of the Hong Kong Stock Exchange (www.hkexnews.hk) and the website of Viva Biotech (www.vivabiotech.com).

Feedback to the Report

Your valuable advice serves as impetus for our continuous improvement. If you have any comments or suggestions on the Report or our related efforts, please contact the Group via the following means:

Tel: +86(0) 21 6089 3288

Fax: +86(0) 21 5824 3936

Website: www.vivabiotech.com

Email: info@vivabiotech.com

CHAIRMAN'S STATEMENT

Dear shareholders,

On behalf of the Board, I am pleased to present the Group's environmental, social and governance ("ESG") report for the year 2025.

Looking back on 2025, the Group achieved steady progress across all its business segments. In CRO business, supported by a moderate recovery in global biopharmaceutical investment and financing and buoyant BD transactions for innovative drugs in the domestic market, new drug developers continued to advance their R&D pipelines and ramp up R&D expenditure, driving a return to positive growth in CRO revenue. Concurrently, amid the deepening integration of artificial intelligence into the biopharmaceutical sector, the Group has fully leveraged AI to empower the entire drug R&D value chain. In the CDMO business, Langhua Pharmaceutical is expected to benefit from the gradual commercialization and surging demand of two newly launched commercial products. In respect of the investment and incubation business, the Group realized successful exits from a number of incubation portfolio companies, generating substantial investment returns and robust cash inflows. Financing for multiple incubated pipelines proceeded favorably, while the incubation of proprietary pipelines has also been formally initiated.

Over the past year, Viva Biotech has continued to provide clients with one-stop integrated solutions spanning early-stage structure-based drug discovery through to commercial-scale drug manufacturing. Upholding a steadfast commitment to ESG principles, the Group has delivered remarkable operational achievements and impressive progress across corporate governance and compliance operation, strategic technological platform deployment, responsible investment, environmental emission reduction, and the advancement of social responsibility initiatives.



Dr. Mao Chen Cheney
Chairman and Chief Executive Officer of Viva Biotech



CHAIRMAN'S STATEMENT

I wish to look back on our operating results and ESG highlights achieved in 2025 together with you:

Results Review:

During the Reporting Period, the Group recorded revenue of RMB1,729.4 million, gross profit of RMB655.6 million and net profit of RMB269.3 million, representing a year-on-year increase of 21.3% compared with the net profit of RMB222.0 million in the same period last year. Adjusted non-IFRS net profit rose from RMB314.6 million in the same period last year to RMB335.3 million, representing a year-on-year increase of approximately 6.6%. Such improvements were primarily attributable to revenue growth in the CRO business, enhanced profitability arising from business structure optimization at Langhua Pharmaceutical, as well as investment income generated from successful exits from incubation portfolio companies.

Corporate Governance and Compliance Operation:

The Group has established a sound corporate governance structure comprising the nomination, remuneration and audit committees, which provide professional guidance and support to the management. Meanwhile, we have formulated a detailed ESG governance structure to ensure that supervision and management are conducted within a standardized and orderly framework. In response to changes in the external environment, we promptly optimize and dynamically adjust our risk management strategies to ensure that control measures are fully implemented across all businesses. The internal audit department also reviews data on major ESG issues to enhance data transparency. In addition, the Company has set up a dedicated anti-fraud task force to define boundaries of non-compliance and corresponding disciplinary mechanisms. Through multiple anti-corruption and integrity training sessions, we strive to foster an open and regulated business environment and strengthen the foundation of ethical operations.

Technological Platform Development:

During the Reporting Period, the Group's R&D investment amounted to RMB100.5 million. In terms of technological platform layout and expansion, the artificial intelligence technologies accumulated and developed by Viva Biotech over the years have been fully integrated to empower its drug discovery platform. At present, its AI capabilities cover the entire process of first-in-class (FIC) drug discovery, and the end-to-end integration of such capabilities has gradually reshaped the paradigm of drug discovery. Focusing on novel targets, new mechanisms of action and innovative molecular formats, the Group has developed distinctive AI capabilities, driving its one-stop original drug R&D service platform to evolve from "AI-assisted" to "AI-driven".

CHAIRMAN'S STATEMENT

Furthermore, during the Reporting Period, the Group successfully held the launch event “Enchantment of Drug Discovery”, where it showcased its self-developed AIDD platform and its three core modules – V-Scepter, V-Orb and V-Mantle – to the industry for the first time, demonstrating its disruptive innovation to the conventional drug R&D process. Meanwhile, the Group entered into an in-depth collaboration with a leading international player to jointly advance a novel AI-driven “dry-wet closed-loop” drug discovery model, which has been successfully and effectively validated. This will lay a solid foundation for future large-scale platform patent licensing collaborations with multinational pharmaceutical companies.

Responsible Investment:

Dedicated to the concept of responsible investment, the Group provided professional post-investment management support, enabling the incubation portfolio companies to achieve smooth progress in their R&D endeavors. As at the end of the Reporting Period, the total number of ongoing pipelines of the Group’s incubation portfolio companies rose to 231, of which 44 had advanced to clinical stages. The Group has cumulatively invested in and incubated 93 start-ups, among which 19 had realized full or partial exits. Through successful exits from certain incubation portfolio companies, the Group obtained cash inflows of approximately RMB83.6 million and recognized investment income of about RMB150.2 million. An additional sum of around RMB205.1 million was received subsequent to the Reporting Period. The Group will make full use of the proceeds from partial exits to advance the incubation of its proprietary pipelines.

Environmental, Energy Conservation and Emission Reduction:

The Group has established a comprehensive Management Process for ESG Material Issue Indicators, which enables effective monitoring and management of material ESG issues and climate-related risks. The CDMO business has set clear short-term emission reduction targets for Scope 1 and Scope 2, which have been validated by the Science Based Targets initiative (SBTi). To ensure delivery against these targets, the Group has formulated a detailed carbon reduction roadmap, optimizing production energy consumption and cutting operational emissions through three major phases and four key initiatives. During the Year, the Group further enhanced Scope 3 emission verification, accurately identified emission hotspots, completed the calculation of Category 1 and Category 2 greenhouse gas emission data, and implemented a series of targeted emission reduction measures. This demonstrates the Group’s resolve to proactively address climate change and advance toward low-carbon operations.

CHAIRMAN'S STATEMENT

Fulfillment of Social Responsibilities:

The Group attaches great importance to talent development and career advancement. In accordance with the Employee Training Management Regulations, we have formulated an annual training blueprint and established a diversified training system covering five special projects. Through layered and categorized skill enhancement programs, we benchmark against international standards to strengthen talent competitiveness and support employees in achieving their career goals. In terms of talent acquisition and motivation, the Group attracts top global talents with a competitive compensation system and clear career paths. Annual grade promotion assessments are conducted regularly on the principles of “fairness, impartiality and openness”, comprehensively evaluating candidates’ integrity, professional capabilities and development potential. This fosters an exceptional workplace environment and achieves common growth between employees and the enterprise.

Viva Biotech has always upheld the organic integration of corporate economic responsibilities with environmental and social obligations. While proactively driving business growth, the Group has embedded ESG principles throughout its entire operations. Adhering to integrity as its core value, the Group has continuously refined its governance structure and ESG governance framework. Concurrently, Viva Biotech integrates sustainable development into every aspect of production and operations, committing itself to emission reduction, efficiency enhancement and resource conservation. We stand ready to collaborate with all stakeholders in building an eco-friendly society and industrial ecosystem.

We firmly believe that the steady growth of the Group stems from the long-term trust and joint efforts of every stakeholder, including shareholders, employees, customers and partners. As the seventh ESG report since the Group’s listing on the Hong Kong Stock Exchange, this Report not only showcases our in-depth practices and achievements in advancing the ESG philosophy during the Reporting Period, but also serves as a sincere response to the expectations of all parties through concrete actions. Looking ahead, the Group will continue to strengthen its operational capabilities and build an irreplaceable competitive moat with its core competencies. Amid its ongoing development journey, the Group will anchor corporate social responsibility deep into its growth trajectory, uphold the mission of “to be innovation-driven, to be empowered by cutting-edge technology, to strive for excellence, and to help patients all around the world”, and strive to realize the vision of “becoming a long-term partner of global innovative biotech companies”.

Dr. Mao Chen Cheney

Chairman and Chief Executive Officer of Viva Biotech

April 22, 2026

STATEMENT OF THE BOARD OF DIRECTORS

Viva Biotech recognizes the importance and necessity of sustainable development for its business, and is committed to improving its sustainability governance system and mechanism and earnestly integrating sustainability requirements into its operations and management, in an endeavor to create sustainable value for employees, shareholders and society. As the highest responsibility owner for managing and publicly disclosing ESG issues of the Company, the Board of Directors (the “**Board**”) plays a leading and supervisory role and assumes full responsibility.

The Group regards ESG and sustainability as a guarantee for its long-term stable development, and incorporates ESG factors into the course of decision-making and daily operations to continuously improve its risk resistance. The Board is the highest responsibility owner and decision-maker for ESG issues of the Group. The Board assumes ultimate responsibility for ESG management policies, ESG strategies, formulation of ESG goals, review of progress towards the goals and ESG performance, and plays a leading and supervisory role in overall ESG strategy and ESG risk management of the Group. In business operation, the Board is responsible for assessing and determining ESG risks, and ensuring that the Group has established an adequate and effective ESG risk management and internal monitoring system. The Board has an audit committee and an ESG management team, mainly responsible for assessing ESG risks related to the Group and ensuring the establishment of appropriate and effective risk management and internal monitoring systems. In the process of supervising the Group’s strategies, major transaction decisions, risk management procedures and related policies, the management fully considers the trade-off assessment of climate-related risks and opportunities.

Directors review and approve our sustainable development goals through regular meetings. Through the ESG management team, directors guide and monitor the development and implementation of our ESG vision, strategy and structure; review important ESG issues, major ESG risks and opportunities; monitor communication channels and methods with shareholders; and review the ESG related disclosures. The Board holds a hearing to review Environmental, Social and Governance Report of the Group annually, and checks the implementation progress against the defined ESG goals.

The Board and all directors warrant that there are no false representations or misleading statements contained in, or material omissions from, the Report and jointly and severally accept responsibility for the truthfulness, accuracy and completeness of the Report. The Report was considered and approved by the Board on April 22, 2026.



ABOUT VIVA BIOTECH

Established in 2008, Viva Biotech (01873.HK) provides one-stop integrated services from early-stage structure-based drug discovery to commercial drug delivery to global biopharmaceutical innovators. As a Contract Research Organization (CRO) service provider with well-established leadership in structure-based drug discovery (“**SBDD**”), we offer leading early-stage to late-phase drug discovery expertise by integrating our cutting-edge technology platforms and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX-MS, CADD, etc. Our team led by senior pharmaceutical chemists and drug discovery biologists provides drug design, pharmaceutical chemistry (H2L, LO), compound synthesis, chemical analysis and purification, kilogram scale-up, polypeptide synthesis and relevant biological activity assay services. Through our subsidiary Langhua Pharmaceutical (“**Langhua**”), we offer our worldwide pharmaceutical and biotech partners one-stop integrated Chemistry, Manufacturing and Controls (CMC)/ Contract Development and Manufacturing Organization (CDMO) services from preclinical to commercial manufacturing. In addition, we are committed to the identification of and investment in biopharmaceutical start-ups with high potential. Viva has embedded an equity for service (EFS) model to high potential start-ups to address unmet medical needs.

As of December 31, 2025, Viva Biotech has provided drug R&D and production services to 2,786 biotech and pharmaceutical clients around the world. We have invested and incubated 93 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers, and improve its R&D and production level and service capacity, so as to provide high-quality and diversified services for more drug discovery start-ups, as well as the medium and large pharmaceutical enterprises around the world. We hope to help more patients through Viva’s platform.



2,786 biotech and pharmaceutical clients worldwide



2,169 employees worldwide



82 domestic and foreign patents



93 portfolio companies

ABOUT VIVA BIOTECH

Technology Platforms

Structural Biology

X-ray (>98,000 structures in total)
Cryo-EM (200+ structures in total)

Protein Science


World-class and Largest in Operation
Proprietary Technology in GPCRs/
Ion Channels/Transporters

Medicinal Chemistry

Classic Small Molecules, Asymmetric Synthesis and/or Chiral Separations, PROTAC Platform, ADC Payload and Linkers, Peptide Synthesis, Isotope Modification, (Bio) Catalyst Screening Technology, Photo Reaction and Flow Chemistry, Electrosynthetic Chemistry, etc.

Pharmacology & DMPK

ADME, PK, Biomarker and Pre-Tox
Efficacy in Tumor,
Autoimmune Disease & Other Areas



CMC & CDMO

API R&D Platform
Drug Product R&D Platform
Manufacturing Plant

AIDD/CADD

De novo design, Virtual Screening (VS),
Molecular Dynamics (MD), FEP for small molecule
design, (Cyclic) Peptides & antibodies,
ADME/PK predictions

Therapeutic Antibody R&D

Integrated Platform Covering Antigen Expression,
Antibody Discovery and Characterization,
High-Throughput Expression, Epitope Mapping,
AI-empowered Antibody Optimization (humanization,
affinity, developability),
ADC/APC/AOC and Peptide Screening

Affinity-based Screening Platform

DEL screening (V-DEL)
Fragment Screening (ASMS, SPR, Crystal Soaking)
Diversity Library Screening (ASMS)
Cys-Targeted Covalent Screening (Intact-MS)
GPCR focused library screening (ASMS)
Peptide Library

Biophysical Technology

State-of-the-art Instruments,
Full Automation and High Throughput

Bioassay Platforms

Biochemical and Cell-based Assays with
Advanced Technologies



ABOUT VIVA BIOTECH

Corporate Culture

We provide one-stop integrated services from early-stage structure-based drug discovery to commercial drug delivery to global biopharmaceutical innovators.



Vision

To become a long-term partner of global innovative biotech companies



Mission

To be innovation-driven, to be empowered by cutting-edge technology, to strive for excellence, and to help patients all around the world



Our values

- Innovation
- Integrity and Professionalism
- Customer Success
- Win-win Cooperation

ABOUT VIVA BIOTECH

Honors and Recognitions

2025 Best Practices Recognition
– APAC Integrated Intelligent Drug Discovery
Technology Innovation Leadership,
by Frost & Sullivan



Top 100 High-Quality Suppliers of
Chinese Pharmaceutical Industry in the
“14th Five-Year Plan” Period



Industry-Leading CRO Company



ESG Excellent Reporting and
Disclosure Enterprise





ABOUT VIVA BIOTECH

Langhua Pharmaceutical’s near-term carbon goal has been officially verified and published by SBTi



DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

Passed the audit by the Pharmaceutical Supply Chain Initiative (“PSCI”)



Langhua Pharmaceutical received an EcoVadis sustainable development rating of “Bronze”



Langhua Pharmaceutical received a CDP climate rating of “B” in 2025



The Group attained an A rating in the Wind ESG assessment



ABOUT VIVA BIOTECH

Overview of ESG KPIs in 2025

Environmental

Scope 2 greenhouse gas emissions: 39,401 tCO ₂ e, a decrease of nearly 6% year-on-year	Diesel consumption: 21,127 liters, a decrease of nearly 93% year-on-year	Non-hazardous wastes generated: 748 tons, a decrease of 10% year-on-year
---	--	--

Calculation and disclosure of
Category 1 and Category 2 data
newly introduced in Scope 3

Social

Gender ratio (male to female): 55%:45%	Percentage of trained employees: 66%	Average training hours per employee: 27.5 hours
---	---	--

Governance

Number of corruption and fraud incidents: 0	Number of major information security and major privacy protection incidents: 0	Business ethics and anti-corruption training rate: 100%
---	--	---



SUSTAINABLE DEVELOPMENT STRATEGIES

ESG Strategies and Goals

Deeply integrating the ESG concept into its operation system as the foundation of sustainable development, Viva Biotech continues to fulfill its commitment to sustainable development by building a growth platform for employees, creating technological value for customers, and delivering sound returns to shareholders. Based on the Group’s strategic plan and actual business operations, we have established a management framework covering five core aspects. This framework systematically connects our ESG goals and business execution paths, employing quantitative indicator monitoring and a dynamic optimization mechanism to ensure that we live up to our long-term vision and ESG mission through implementation across all levels of the Group:



SUSTAINABLE DEVELOPMENT STRATEGIES

ESG Governance Structure

To effectively promote the implementation of sustainable development strategies, the Group has established a robust three-tier governance structure, covering decision-making, management and execution levels. By clearly defining management functions at various levels in sustainable development matters, the Group is committed to continuously improving its sustainable development governance, to ensure that its ESG supervision and management work is carried out within a standardized and orderly framework.

Board of Directors: As the highest decision-making body of the Group, it plays a key leading role in formulating sustainable development strategies and making major decisions, and assumes ultimate responsibility.

Audit Committee: As appointed and authorized by the Board, it assists the Board in monitoring and reviewing relevant policies, management processes and actual performance of the Company's various ESG matters. The committee also supervises and manages the overall risk management and internal control system of the Company. The committee meets at least once a year for review and approval of major ESG matters and annual ESG reports, to ensure the accuracy and compliance of information disclosure.


ESG management team: The ESG management team supervises the effective implementation and promotion of various ESG policies and matters in accordance with the ESG related strategies and management policies established by the Audit Committee. It reports to the Audit Committee at least once a year on the progress of ESG supervision work and major issues identified, and provides corresponding recommendations as important reference for decision makers. To ensure that the commitment members have relevant professional competence, a presentation or training session covering topics such as climate change was provided to them during the Year to deepen their understanding of ESG trends and climate risks.

ESG working group: The ESG working group is composed of department heads, responsible for coordinating the specific implementation of the ESG work plan to ensure steady progress of all work streams. It optimizes and implements various ESG management requirements issued by the management, and reports the implementation of various rules and the progress towards goals to the management at least twice a year. It also holds ad hoc special meetings according to specific issues and departmental needs, to address sustainable development challenges in daily operations.



SUSTAINABLE DEVELOPMENT STRATEGIES

ESG Governance Structure



SUSTAINABLE DEVELOPMENT STRATEGIES

Communications with Stakeholders

Stakeholders' opinions are a key input to sustainable corporate development. Viva Biotech has established a sound and smooth communication channel, maintains effective interaction with all stakeholders in an open and transparent manner, listens to them and actively responds to the common concerns of all parties in order to continuously optimize its sustainability strategy and management methods, earnestly fulfill its corporate social responsibility, and create more value for its stakeholders. During the Reporting Period, we reviewed and confirmed seven types of most important stakeholders based on the two dimensions of “impact by the Group” and “impact on the Group”. The following table sets forth in detail the concerns of various stakeholders, as well as the communication channels and specific responses of the Group.

Stakeholders	Issues of concern	Communication channels and response of the Group
Government and regulators	<ul style="list-style-type: none"> • Compliance with laws and regulations • Promote employment • Drive local economic development • Address climate change 	<ul style="list-style-type: none"> • Abide by laws and regulations and strictly implement the government's policy requirements • Actively participate in government-enterprise cooperation projects
Shareholders/investors	<ul style="list-style-type: none"> • Information disclosure • Financial performance • ESG governance 	<ul style="list-style-type: none"> • Convene general meetings • Improve information disclosure and issue financial reports and other special reports • Hold investor conferences, conduct roadshows and reverse roadshows, publish newsletters or WeChat official account articles, and communicate online
Portfolio companies/clients	<ul style="list-style-type: none"> • Product quality and safety • Privacy and security • Intellectual property protection • Efficient delivery • Increase R&D investment 	<ul style="list-style-type: none"> • Improve the customer service mechanism • Conduct customer satisfaction surveys • Organize regular visits to customers • Regular teleconferences
Suppliers	<ul style="list-style-type: none"> • Fair trading • Win-win cooperation 	<ul style="list-style-type: none"> • Improve the procurement and tender system • Strengthen supplier management and annual supplier evaluation



SUSTAINABLE DEVELOPMENT STRATEGIES


Stakeholders	Issues of concern	Communication channels and response of the Group
Business partners	<ul style="list-style-type: none"> • R&D platform and investment • Supply chain management 	<ul style="list-style-type: none"> • Hold meetings for communication • Actively participate in industry cooperation and exchanges
Employees	<ul style="list-style-type: none"> • Compensation and benefits • Occupational Health and Safety • Employment compliance • Talent attraction and retention • Career development and growth 	<ul style="list-style-type: none"> • Employ staff legally, formulate and implement sound employment policies • Provide comprehensive and competitive compensation and benefits • Provide comprehensive safety protection for employees and strictly implement epidemic prevention and control policies • Hold employee communication meetings regularly • Set up an employee suggestion box • Improve the training system and carry out training activities
Media	<ul style="list-style-type: none"> • Information disclosure and transparency 	<ul style="list-style-type: none"> • Hold press conferences • Attend media events and accept media interviews

Materiality Assessment

To systematically review the Group’s strategic commitments, institutional framework and practical effectiveness in sustainable development and actively respond to the core concerns of stakeholders regarding ESG governance, we have established a normalized evaluation mechanism and continuously identify material ESG issues of strategic value through regular questionnaire surveys. Our evaluation work for the Year adopts dual materiality matrix analysis, which not only focuses on financial impact of the issues on our sustainable development, but also attaches importance to their environmental and social effect. We also ensure that these issues of concern are well aligned with the United Nations Sustainable Development Goal(s) (“UNSDG(s)”) and the expectations of stakeholders.


SUSTAINABLE DEVELOPMENT STRATEGIES

Materiality assessment process:





SUSTAINABLE DEVELOPMENT STRATEGIES



Based on the materiality matrix, during the Reporting Period, we identified a total of 10 highly material issues, 11 moderately material issues and 1 low material issue. The Report will respond to and disclose the material issues, particularly all the highly material issues.

SUSTAINABLE DEVELOPMENT STRATEGIES

Importance	Issues	Relevant sections
Highly material issues	Hazardous and non-hazardous waste management	4.3 Waste Management
	Employee compliance, diversity and inclusiveness	5.2 Diversity, Equality and Inclusiveness
	Employee health and safety	5.3 Occupational Health and Safety
	Talent attraction and retention	5.4 Human Capital Development
	Employee rights and benefits	5.1 Employment Compliance and Employee Benefits
	Intellectual Property Management	2.2 Intellectual Property Management
	R&D and technological innovation	2.1 R&D and Innovation
	Product quality and safety	2.3 Quality Management
	Information security and privacy protection	2.5.3 Privacy Protection and Information Security
	Sustainable supply chain management	2.6 Sustainable Supply Chain
Moderately material issues	Greenhouse gas emission and management	4.2 Energy Conservation and Emission Reduction Actions and Measures
	Natural resource use and management	4.4 Resource Management
	Energy use and management	4.2 Energy Conservation and Emission Reduction Actions and Measures
	Address climate change	4.1 Supporting the Climate Actions
	Biodiversity	4.4 Resource Management
	Employee development and training	5.4 Human Capital Development
	ESG governance system	ESG Governance Structure
	Responsible Investment	3.1 Responsible Investment
	Business Ethics and Anti-corruption	1.2 Business Ethics and Anti-corruption
	High-quality customer service	2.5 Protection of Clients' Rights and Interests
Low material issues	Industry cooperation and co-construction of ecosystem	3.2 Promoting Industry Cooperation
	Community Investment	5.5 Community Responsibility and Contribution



SUSTAINABLE DEVELOPMENT STRATEGIES

Alignment with United Nations Sustainable Development Goals

In working on a number of sustainability issues, the Group actively contributes to ensure that our efforts are closely aligned with the UNSDGs, thereby making a meaningful contribution to global sustainable development.

Aspect	Corresponding UNSDGs	Relevant material issues	Our actions
Commitment to responsible corporate governance		<ul style="list-style-type: none"> ESG governance system Business ethics and anti-corruption 	<ul style="list-style-type: none"> Establish a systematic ESG governance structure Establish a business ethics supervision mechanism and an anti-fraud working group to deepen integrity management
Innovation-driven approach to shared value creation		<ul style="list-style-type: none"> R&D and technological innovation Intellectual property management Quality management and safety High-quality customer service Information security and privacy protection Sustainable supply chain management 	<ul style="list-style-type: none"> Build up a cluster of pharmaceutical innovative technology platforms and an industrial collaboration network Implement a full lifecycle quality management system to ensure drug safety and compliance Improve our patent portfolio strategy and strengthen the protection for core technologies
Industry leadership and multi-dimension empowerment		<ul style="list-style-type: none"> Responsible investment Industry cooperation and co-construction of ecosystem 	<ul style="list-style-type: none"> Establish an investment ESG evaluation system to strike a balance between economic benefits and social value Deepen exchanges with various institutions and promote in-depth industry-university-research collaboration
Environmental benefits and ecological protection	  	<ul style="list-style-type: none"> Address climate change Greenhouse gas and waste gas emission and management Energy use and management Waste management Natural resource use and management 	<ul style="list-style-type: none"> Implement the action plan on green operation and establish a low-carbon production system Optimize pollution prevention and control technology solutions to realize full-process monitoring of emissions Promote the circular economy model to improve utilization rate of recycled resources
People-oriented and harmonious community	 	<ul style="list-style-type: none"> Employee rights and benefits Employee compliance, diversity and inclusiveness Employee health and safety Employee development and training Talent attraction and retention Community investment 	<ul style="list-style-type: none"> Create a diverse and inclusive workplace ecology, and improve the fair development mechanism Establish an occupational health and safety management system to prevent occupational risks Develop a tiered talent cultivation plan and improve the talent reserve system

1. COMMITMENT TO RESPONSIBLE CORPORATE GOVERNANCE

Viva Biotech incorporates corporate governance excellence into its core strategy, to ensure decision-making transparency by establishing a rigorous multi-level internal control framework. The Board actively improves the anti-corruption and compliance system, drawing upon a comprehensive business ethics review and conflict of interest management mechanism to guide our R&D cooperation and business dealings in full alignment with the highest international and domestic standards. We always adhere to honest operation to ensure that our enterprise pursues sustainable growth on a fully compliant track.

Corresponding UNSDG:



1.1 Corporate Governance


Adhering to high corporate governance standards, the Group is committed to safeguarding shareholders' rights and interests, enhancing corporate value, and continuously strengthening transparency and accountability mechanisms by developing efficient business strategies and policies. The Group strictly abides by the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Corporate Governance Code contained in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and other relevant laws and regulations.

Board Governance Structure

The Board has established the Nomination Committee, the Remuneration Committee and the Audit Committee to provide professional guidance and support to the management. The Board comprehensively monitors our operating conditions and financial performance by setting strategic goals and supervising execution, to ensure sound operation of our internal monitoring system and risk management mechanism. The terms of reference of each committee have been published on websites of the Company and the Hong Kong Stock Exchange and are available for inspection by shareholders.



1. COMMITMENT TO RESPONSIBLE CORPORATE GOVERNANCE



1. COMMITMENT TO RESPONSIBLE CORPORATE GOVERNANCE

Board Diversity

The Group has adopted the Board Independence and Diversity Policy, which defines the principles of Board composition and the implementation methods. The relevant functional organ is responsible for specific implementation, such as regularly evaluating the Board structure based on the standards above and continuously optimizing composition of the Board members, with an aim to improve decision-making quality through the combination of diverse backgrounds. In the talent selection process, the Nomination Committee considers multidimensional factors including but not limited to personality traits, age distribution, cultural perspectives, education level, professional qualifications, skills and expertise, knowledge structure, industry experience and regional operational experience, so to ensure that the Company has forward-looking strategic insights on the basis of sound operation. The Board will continue to monitor the effectiveness of policy implementation, make adjustments and optimizations through a dynamic review mechanism, and thus strengthen our response capabilities to ESG issues at the decision-making level, laying a solid governance foundation for achieving sustainable development goals.

As at the end of the Reporting Period, the current Board consisted of eight members, including three executive directors, two non-executive directors and three independent non-executive directors. The inclusion of one female director in Board composition reflects the Group's emphasis on gender diversity and balanced governance.



1. COMMITMENT TO RESPONSIBLE CORPORATE GOVERNANCE

1.2 Business Ethics and Anti-corruption

The Group is committed to establishing an open and standardized business environment and regards business ethics as the core of corporate responsibility. We strictly abide by the requirements of the Corporate Governance Code, the Criminal Law of the People's Republic of China, the Company Law, the Anti-unfair Competition Law and relevant regulations, and always uphold integrity in supply chain management and social interaction.

To effectively prevent corruption and money laundering risks, we have established a dedicated anti-fraud working group and developed the Anti-money Laundering Management System and the Anti-fraud Management System, to clarify the boundaries of violations and punishment mechanism. The Audit Department, as a core executing organ, takes the leading role in annual fraud risk assessment, review of major projects and anti-fraud publicity. Meanwhile, the Group requires its employees holding key positions to sign the Anti-bribery/Anti-corruption Commitment Letter upon joining the Group, to jointly maintain the positive business culture and corporate image of the Company. During the Reporting Period, three executive directors and nearly 100 employees signed the commitment letter, setting an example as led by the management to sustain a clean culture.

To strengthen the compliance awareness of all employees, the Group held several anti-corruption and integrity training sessions with a focus on the establishment of a mechanism for identifying and reporting false reimbursement claims. During the Reporting Period, as many as 2,169 employees participated in the training sessions. Through the analysis of judicial precedents, we further clarified the legal cost of corruption and successfully established a corporate culture of integrity and honesty.

Whistleblowing and Investigation Mechanism

To ensure smooth communication and feedback from external stakeholders on compliance and business ethics, the Group has established sound and transparent channels for complaint and whistleblowing. Employees and relevant stakeholders may blow the whistle on frauds, violations of professional ethics, accounting and auditing irregularities in real names or anonymously through diversified channels such as telephone hotline and email. We have established an anti-fraud working group to handle the whistleblowing information, including strictly implementing the standardized procedures for case acceptance, registration, written records and reporting to the Audit Committee, and actively assist in the investigation process. The entire handling process follows the principle of confidentiality. As clearly specified by the Group, it is strictly prohibited to divulge identity of the whistleblower and the information provided, or disclose details of the case to the accused party. It is prohibited to present the original or photocopy of any materials submitted anonymously, which shall not undergo handwriting identification, in order to ensure that the legitimate rights and interests of the whistleblowers are protected adequately.

1. COMMITMENT TO RESPONSIBLE CORPORATE GOVERNANCE

Any verified irregularities will be promptly stopped, dealt with, and escalated to relevant authorities by the Group. In case of a suspected criminal offence, the case shall be referred to a judicial authority according to law, to demonstrate our firm stance in maintaining a clean culture. After receiving a complaint, the Internal Audit Department will initiate the appropriate handling and investigation process as follows:

The Internal Audit Department keeps a written record of the receipt, storage, and handling of reports from employees, either explicitly or anonymously, or from external third parties, either explicitly or anonymously. The identity of the whistleblower and the information provided are kept in strict confidence.



The Internal Audit Department will submit written records to the Audit Committee and will assist the committee in its investigation of the complaint or allegation.



If an in-depth investigation is required, the Audit Committee will deploy resources to investigate into the incident in an effective and timely manner.



If the report is substantiated after investigation, we will stop or address any non-compliance found in a timely manner and report the situation to the relevant departments. Suspected criminal offenses will be referred to the judicial authorities for action.

Whistleblowing and investigation process

During the Year, the Group did not receive any relevant complaints or reports. In case of any complaints or reports, the Internal Audit Department will handle and address them in a timely manner in accordance with the relevant complaint and whistleblowing process. In addition, we did not receive any reports or judicial proceedings against the Group or its employees in relation to corruption, bribery, extortion, fraud or money laundering.

Whistleblowing method

Whistleblowing email:

✉ fanwubi@vivabiotech.com



1. COMMITMENT TO RESPONSIBLE CORPORATE GOVERNANCE

1.3 Risk Management

The Group is committed to building a robust risk prevention and control barrier, deeply integrating information security and privacy protection into operational details. Under the framework of the Company Law and the Articles of Association, the Group has formulated core policies such as the Basic Standards for Internal Control, the Risk Management System, and the Business Continuity Management. The Board takes overall charge of assessing the Group’s risk appetite and overseeing its compliant and effective internal control system.

To ensure implementation of the system, we adopt risk-oriented internal audit to manage existing and new risks in real time. Meanwhile, we strictly comply with the Anti-unfair Competition Law and the U.S. Foreign Corrupt Practices Act (FCPA), and include a special audit on fraud risk in the annual audit process to strengthen protection for compliance. The Internal Audit Department works closely with the Audit Committee to conduct in-depth investigations into material issues, ensuring that the risk management system effectively supports development and strategic goals of our enterprise.

Board of Directors	Manage and monitor the risk management and internal control systems
Audit Committee	Guide risk avoidance, and supervise and verify the implementation and effectiveness of risk management and internal control systems
Internal Audit Department	Lead the risk management and internal control of day-to-day operations and establish a risk avoidance and internal control system to improve the Group’s operation and management process and effectively address and reduce overall operational risks
Various departments	Monitor and manage daily operational processes and procedures, identify major risks, conduct self-inspection, and implement main monitoring processes

1. COMMITMENT TO RESPONSIBLE CORPORATE GOVERNANCE

ESG risk management

The Group closely monitors macro policies, market dynamics and industry trends under a regular monitoring mechanism. In response to significant changes in the external environment, we promptly optimize and dynamically adjust our risk management strategies to ensure that relevant management measures are fully implemented across all business lines. Through precise risk identification and flexible strategic deployment, the Group is committed to maintaining operational resilience in times of change and building up a risk defense line for sustainable development to ensure sound business growth.

To effectively address major ESG issues and related risks, the Group has established a dedicated monitoring and management mechanism. We have selected highly material issues as the focus of reporting, and established a “hierarchical early warning mechanism” for key indicators of the following issues.

Major ESG issues	Indicators
Waste management	Total hazardous wastes generated and intensity
	Total non-hazardous wastes generated and intensity
Employee compliance, diversity and inclusiveness	Gender ratio
Employee health and safety	Lost days due to work injury
Talent attraction and retention	Personnel turnover rate
R&D and technological innovation	R&D investment as a percentage of revenue
	Number of patents granted
Information security and privacy protection	Number of security incidents/customer complaints

When a relevant indicator touches the warning line, the Group will initiate standard response procedures: Firstly, the Internal Audit Department and the ESG working group verify accuracy of the data. If the situation is serious, it will be reported to the CEO or the Board of the Group for review, and relevant functional departments will be convened for a special meeting to analyze the reasons in depth. Subsequently, the Internal Audit Department will combine data analysis and conclusion of the meeting to prepare a written report, and put forward suggestions for improvement.



1. COMMITMENT TO RESPONSIBLE CORPORATE GOVERNANCE

In addition, the Internal Audit Department conducts an annual review of relevant data on major ESG issues, paying special attention to any indicator whose changes from the previous year have reached the warning line, so as to ensure continuity and effectiveness of risk management work. The ESG indicator audit work performed by the Internal Audit Department in the Year included:

- Check and compare annual environmental and social data with last year, and understand the data collection and record information to ensure authenticity of the data
- Examine the key areas to be optimized in ESG policies and measures, including environmental (e.g. carbon emissions, waste management), social (e.g. labor relations management, data privacy), and governance (e.g. corporate governance, business ethics) aspects
- Provide recommended improvements to help optimize our ESG management process

2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

Deeply rooted in the biopharmaceutical forefront, Viva Biotech draws upon its outstanding technological R&D capabilities with a high sense of responsibility to fuel sound business development. We provide customers with one-stop services covering early R&D to commercialized production, and regard honest operation and quality excellence as the foundation of our business development. By continuously optimizing service processes and improving technical standards, the Group is committed to exceeding customer expectations and enhancing trust in cooperation. We further adopt an open stance and invite global innovation partners to join our cooperation platform. Through resource integration and collaborative innovation, we aim to build a mutually beneficial and prosperous biopharmaceutical ecosystem, seeking value creation in a higher dimension across the industry.

Corresponding UNSDG:



2.1 R&D and Innovation

With an unchanged focus on R&D innovation, our CRO business has consolidated its leadership in early R&D by strategically deploying cutting-edge technologies such as biophysics and Cryo-EM, combined with pharmaceutical chemistry and computer-aided drug design. In the CDMO sector, we continuously optimize production processes through automation technological modifications and upgrades.

We have established diversified platforms including proteolysis targeting chimera (“**PROTAC**”) technology platform, biological activity assay (“**Bioassay**”) platform, therapeutic antibody discovery technology platform, API R&D platform, preparation R&D platform, production platform, etc., achieving a complete cycle from R&D to commercial delivery. Relying on its strong R&D team and advanced infrastructure, the Group continues to enhance its one-stop service chain. To maintain our technological leadership, we invested R&D expenditure of RMB100.5 million during the Reporting Period, to pursue breakthroughs against technological barriers and fuel global pharmaceutical innovation.



2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION


2.1.1 AIDD/CADD Platform

Regarding our AI-enabled SBDD one-stop R&D service platform for innovative novel drugs, our computer-aided drug discovery (CADD) and artificial intelligence drug discovery (AIDD) platforms employ physical chemistry models and artificial intelligence algorithms to enable the development of various modalities and help advance drug R&D projects rapidly and efficiently, based on a deep understanding of structures and MOAs to truly practice computation-driven drug R&D. Structures and MOAs, as unique technological strengths of Viva's AIDD platform, can play a significant role in the research of new targets, complex MOAs and various drug modalities. Our computing platform has developed a series of advanced algorithms specific to challenges in project development to solve practical problems in drug design such as covalent and non-covalent free energy perturbations, resulting in higher computational accuracy and larger adjustable parameter range. Addressing gaps in the traditional computational chemistry methodology, the computing platform introduced generative artificial intelligence algorithms, which break through the limitation of chemical space with ab initio generation, enabling drug design to achieve the breakthrough from zero to one with the aid of computation. Furthermore, ADME/PK prediction models were developed under the platform, enabling comprehensive coverage of various drug R&D stages and systematic integration of computing tools. The methods developed under the computational chemistry and artificial intelligence platform have been applied in the R&D of various drug modalities, such as micromolecule, antibody, peptide, PROTAC and molecular gels, and targeted RNA micromolecule drugs. In the process of algorithm development, our platforms maintain the linkage of dry and wet experiments and the computational results are verified through experimental validation, during which computational models are iteratively optimized to ultimately achieve breakthroughs. In particular, for complex modalities such as peptides, the Company has built an end-to-end integrated platform that enables automated 3D peptide modeling, precise substitution of non-canonical amino acids (NCAA) and the development of complex cyclization strategies. This automated intelligent module not only supports trillion-scale library screening, but has also shortened R&D cycles to one-third of the traditional ones and reduced R&D costs by 50% to 70% in practical applications. Through high-frequency integration of dry and wet experiments, the platform has successfully delivered a number of candidate molecules with picomolar affinity, significantly improving the efficiency and success rate of peptide drug discovery and setting a new benchmark for AI-driven peptide drug discovery. Generally, Viva's CADD and AIDD platforms have the capability to develop proprietary algorithms and enhance platforms and the experience in exploring various drug modalities, and fully leverage our advantages in structure-based drug discovery, which can comprehensively empower various early drug R&D aspects with the computing power supported by Viva Shanghai's supercomputing cluster.

2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

Regarding the evolution stage of artificial intelligence platforms, Viva is shifting from computation-enabled to a new AI-driven paradigm, i.e. leveraging AI-driven experiments to redefine the paradigm of drug design. So far, our artificial intelligence platform has realized a wholly new design process with interlinked dry and wet experiments, breaking the restrictions from the original R&D cycle and providing a new impetus to innovative drug design, and has reached well-known collaboration cases on packaged AI discovery solutions in certain niche segments. Furthermore, the Group successfully held the “Enchantment of Drug Discovery” launch event during the Reporting Period, where it unveiled its self-developed AIDD platform for the first time. The event provided in-depth insights into the platform’s unique advantages, its disruptive innovation to traditional drug discovery workflows, and its three core functional modules of V-Scepter, V-Orb and V-Mantle. Integrated with cutting-edge algorithms dedicated to multimodal design and automated modules, the platform demonstrated industry-leading affinity prediction accuracy and delivery capabilities in the design of peptide-drug conjugates (PDC) and cyclic peptide drugs. Through case demonstrations, the Company further showcased the platform’s boundless potential in real-world applications, laying a solid foundation for securing major AI-related orders in the future.


AIDD/CADD platform: Three core functional modules






2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

AI-driven Drug Design




R&D Milestones of Viva Biotech



2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

2.2 Intellectual Property Management



Viva Biotech adopts a “zero tolerance” stance towards intellectual property infringement. In promoting its innovation-focused business activities aiming for win-win cooperation, the Group has established and implemented a comprehensive intellectual property management system and an infringement accountability mechanism. By applying industry-leading protection practices across our global operating sites, we continuously strengthen our core competitiveness to cement customer trust in the Group.

The Group strictly abides by the Patent Law of the People’s Republic of China, the Trademark Law of the People’s Republic of China, the Copyright Law of the People’s Republic of China and other domestic laws and regulations. As a biopharmaceutical company targeting the international market, we also strictly comply with the Patent Cooperation Treaty and other relevant international treaties and agreements. Also, the Group has established a dedicated intellectual property department. The department, composed of professional personnel, undertakes the responsibilities of formulating intellectual property development plans, establishing a relevant management performance evaluation system, supervising and assessing relevant bodies, and comprehensively coordinating our intellectual property matters, to ensure that the Group’s innovative achievements are fully protected.

Furthermore, the Group has formulated systematic intellectual property control procedures to fully strengthen intellectual property protection responsibilities across four dimensions: resource management (human resources, finance, information, etc.); basic management (acquisition, maintenance, contracts, confidentiality, etc.); implementation and operation (project initiation, R&D, procurement, sales, etc.); audit and improvement. Through efficient management throughout the entire process, the Group has effectively prevented the risks associated with internal and external infringements and ensured robust protection of its core innovation achievements.



2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

Intellectual property protection measures:

Resource Management	<ul style="list-style-type: none"> All employees have signed confidentiality agreements and non-compete agreements; Regularly conduct intellectual property related training and exams.
Basic management	<ul style="list-style-type: none"> Prevent unauthorized copying of documents through an encryption system; Encrypt and keep traceable all documents issued by R&D units; Strictly manage folder access permissions.
Implementation and operation	<ul style="list-style-type: none"> Adopt access control and all-round, all-weather camera monitoring for classified areas; Strictly manage acquisition, transmission and distribution of information during project management; Require suppliers and service providers to strictly comply with the confidentiality agreements concerning intellectual property reserves in accordance with the Management Measures for the Protection of Trade Secrets.

2.3 Quality Management

2.3.1 Quality Management System

Viva Biotech recognizes that product quality is the cornerstone of an enterprise. We continuously enhance our quality management capabilities and strictly comply with domestic and foreign laws and regulations concerning production and quality. In addition to implementing the Product Quality Law, we deeply fulfill the requirements of the Drug Administration Law and China’s Good Manufacturing Practice (GMP) for pharmaceuticals, incorporating quality accountability into the accuracy and reliability of our services to provide solid support for industry innovation.

Langhua Pharmaceutical, a CDMO business platform of the Group, has built up a strong advantage in international market access thanks to its well-established quality system. Its API products have not only fully obtained China GMP certification, but also gained recognitions from authorities including FDA, WHO, EDQM and the European Union. This marks that Viva Biotech is fully capable of providing high-standard R&D and manufacturing services to the world’s top pharmaceutical companies and has become their long-term strategic partner.

2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

To further strengthen drug safety control, the Group has formulated and implemented a series of key management procedures:

- **Impurity control:** In accordance with the Management Procedures for the Assessment and Control of Genotoxic Impurities, we conduct systematic risk assessments on raw materials, intermediates, by-products and other substances, and ensure scientific validity of testing methods through supplier verification.
- **Laboratory inspection management:** In addition, we follow the QC Procedures for Laboratory Inspection Process Management, which defines standardized procedures covering the entire workflow including submission, storage, inspection and disposal of samples, to effectively prevent environmental contamination or cross-contamination.

Through strict implementation of the systems above, Viva Biotech ensures the integrity and validity of testing data, enabling us to continuously provide safe, consistent and high-quality products to the global biopharmaceutical market.

2.3.2 Recall Procedures

To effectively address potential product quality risks, the Group has established standardized quality review, emergency response and recall procedures. The Group regularly reviews its internal standards to ensure scientific validity and timeliness of the quality control system. We embed the principle of quality priority into all operational dimensions covering risk management, internal audit and error correction and staff training, to establish an efficient and coherent quality control closed loop. Through relentless pursuit of product quality and safety standards, we ensure that every delivery meets safety and efficacy requirements, to empower customers and the industry on an ongoing basis.

We have established the Administrative Measures on Drug Recalls to standardize the product recall procedures. Once potential safety hazards are identified through investigation and risk assessment, or upon receipt of a recall order from regulatory authorities, the Group will immediately activate the response mechanism. After assessing the risk, the recall team will define the recall level and request each department to formulate and implement detailed recall plans. During implementation, the Group will promptly notify relevant customers, prepare dedicated storage facilities, and carefully verify the quantities and batch numbers of recalled products to ensure accuracy. Where necessary, we will seek assistance from the public and drug regulatory authorities. Upon the return of products to warehouse, the quality department will organize investigation, prepare a summary report, and propose corresponding corrective and preventive actions in accordance with the Corrective and Preventive Measures Management Regulations. The Group will report to relevant government authorities when required, to prevent recurrence of similar issues and fully safeguard public drug safety.



2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

The Group has not experienced any product recalls for health and safety reasons during the Reporting Period.

Case Highlight: Viva Biotech Wins the Quality Excellence Award

In 2025, Viva Biotech was honored with the Quality Excellence Award at the 2025 Mindray Supplier Quality Conference & Phase 6 of Quality Academy hosted by Mindray Medical, in recognition of its outstanding R&D capabilities and rigorous quality management system. At the conference, our CEO Dr. Ren Delin was invited to share “The Quality Management Philosophy of Viva Biotech”, elaborating in depth on the Company’s commitment to high quality.

In R&D, Viva Biotech has established a comprehensive R&D system with highly customized development capabilities, enabling precise modification of chemical structures and performance enhancement. In terms of production and compliance, the Company has successfully passed 14 audits by global authorities including FDA, EDQM, WHO, ANVISA, PMDA and NMPA. We have built a full-process assurance system spanning early-stage R&D to stringent quality control, consistently delivering high-quality services meeting international standards to global partners.




2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

2.4 Animal Welfare and Rights

2.4.1 Experimental Animal Management System

Viva Biotech adheres to the highest standards of laboratory animal welfare while advancing pharmaceutical innovation. We adopt a responsible and humane approach and strictly comply with the laws, regulations and ethical guidelines of the jurisdictions where we operate. We have defined standard operating procedures under the Regulations on Experimental Animal Management, as overseen by the Experimental Animal Management Committee appointed by the President. The committee comprises diverse members to ensure that research value and social justice are well balanced in the assessment process, with transparent and regular communication on animal welfare.

To ensure every experiment is ethically sound, we adopt the principle of “approval before experiment”. All experimental projects should have the Experimental Animal Research Plan and the Experimental Animal Welfare and Ethics Review Form submitted before initiated, and must be approved by the committee before purchasing animals and conducting experiments. In terms of personnel qualification, all laboratory personnel must obtain dual professional certifications from government authorities and the Group before assuming their positions. For any violation of the rules and regulations, the Group has established a disciplinary mechanism including warnings, suspension or revocation of qualifications to strengthen accountability. We will continue to optimize the approval and training system, to ensure that animal experiments are in compliance with international ethical standards throughout the process.





2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

2.4.2 Animal Welfare Initiatives

The Group strictly implements the principle of “3R” (replace, reduce, refine) in all animal experiments, and prioritizes non-living alternatives to reduce the use of animals. In terms of feeding management, we not only comply with national standards but also set limits on feeding density and the social interaction norms specific to animal species, to reduce animal stress responses effectively. In addition, the Group has established an all-weather environmental monitoring system to ensure precise implementation of constant temperature, ventilation and regular disinfection procedures for animal houses. Through a scientific and humanized management mechanism, we comprehensively maintain physiological and behavioral health of animals to fulfill our corporate ethical responsibilities.

2.5 Protection of Clients’ Rights and Interests

2.5.1 Customer Services

The Group regards customer feedback as a core driver to enhancing service quality and is committed to delivering excellent customer experience. In marketing activities, the Group adheres to the principle of ethical, scientific and objective practices, and strictly comply with the Advertising Law of the People’s Republic of China and relevant laws and regulations. By implementing rules such as the Brand Strategy Management System and the Anti-unfair Competition and Fair Marketing Procedures, we ensure that all marketing materials are reviewed strictly and meet the requirements of authenticity and scientific validity, and prohibit false advertising resolutely. During the Reporting Period, the Group was not involved in any legal proceedings related to false marketing.

Leveraging its profound expertise in CRO and CDMO, the Group has established a comprehensive system covering R&D to production and delivery, to offer high-quality solutions to global customers. We value in-depth interaction with customers and have established a multidimensional communication mechanism to ensure timely resolution of issues. Through systematic satisfaction surveys, we continuously track service performance, especially on key indicators such as intellectual property protection and response efficiency. During the Year, we achieved a customer satisfaction score of 98. This not only affirms our professional services but also strongly demonstrates the Group’s relentless pursuit of excellence and value creation with customers.

2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

2.5.2 Customer Complaint Mechanism

The Group is committed to establishing a smooth channel for customer service complaints. We have formulated the Operational Procedures for Handling Customer Complaints and the Complaint Management Regulations to specify the complaint handling process and feedback mechanism, to ensure that every complaint is handled in an efficient and standardized manner. Upon receipt of a customer complaint, the Group will immediately organize in-depth discussions with relevant department heads, project managers, the Internal Control Department and the Customer Service Department to assess the adequacy and reasonableness of the complaint information. Complaints are managed by category: Quality-related complaints are handled with reference to recall procedures, to assess whether a product recall should be initiated; and non-quality complaints will be properly addressed through measures specific to case situations to improve customer satisfaction continuously.

To ensure premium customer service, we have made the following undertakings:



To enhance service quality, the Group has established a systematic evaluation mechanism to regularly summarize experience in handling customer complaints and refine operation management and business efficiency accordingly. We adhere to innovation-driven improvement and fully respond to customer needs through process optimization and quality enhancement, to secure our service leadership in the industry. The Group did not receive any major complaints from customers during the Reporting Period.



2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

2.5.3 Privacy Protection and Information Security

The Group strictly complies with the Cybersecurity Law of the People's Republic of China, the Data Security Law of the People's Republic of China, the Personal Information Protection Law of the People's Republic of China and relevant laws and regulations. Based on the Standards for Computer Information Security Management and the Information Security Management Manual, the Group newly adopted the Information Security Incident Management Procedures and the Regulations on IT Emergency Response Process during the Year, aiming to establish a sound reporting, response and handling mechanism for information security incidents. By standardizing operational procedures for emergencies and taking effective corrective and preventive measures, the Group is able to minimize the losses from security incidents. In terms of organizational structure, a dedicated information security team has been set up under the General Administration Department, responsible for issuing relevant management documents, conducting information security training, and centrally managing the investigation, handling and follow-up improvement of security incidents. In addition, the Group has successfully obtained ISO 27001 information security management system certification. This marks that our efforts in safeguarding corporate information security and privacy protection have been recognized against international standards, laying a solid foundation for sound business operations and data security.

2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

Key information security measures:

Standardize full-lifecycle process and operations	<p>The Group strictly standardizes the operational procedures of employees in aspects including information collection, storage, sharing, use and destruction, and specifies relevant provisions on privacy protection in the management system, so as to ensure that every stage of data processing meets compliance and security standards.</p> <p>The Group has established comprehensive guidelines for large model usage, specifying rules and restrictions on applicable scenarios, data desensitization, classified data management, code-compliant use and handling of violations. Through standardized management, we guide employees to adhere to security bottom lines while leveraging cutting-edge technologies, jointly protecting the Company's information security and core interests.</p>
Enhance company-wide security awareness	<p>We provide diverse information security training activities, including new-hire onboarding training, phishing simulation acknowledgments and regular information security updates, aiming to strengthen employee awareness of safeguarding information security, reduce human-induced security risks at the source and build a solid security defense line.</p>
Improve partner confidentiality management	<p>For suppliers and customers, the Group has formulated the Basic Rules for Partner Confidentiality Management and the Guidelines for Confidential Information Transmission with Partners, clearly defining confidentiality requirements across business scenarios and the full process. Relevant parties are required to sign confidentiality agreements or commitment letters to ensure the security of trade secrets and sensitive information.</p>



2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

The Group continuously strengthens customer information security management and implements various protection measures in accordance with the Regulations on Confidentiality of Customer Information. In clinical research, we strictly implement the informed consent process to ensure that all participants voluntarily sign agreements after fully understanding trial information, with their rights and interests fully protected. The Group is committed to upholding high standards of data ethics. During the Reporting Period, the Group did not receive any complaints regarding infringement of customer privacy or loss of customer data, and successfully achieved the annual security management objectives, fulfilling our security commitment to customers and society on an ongoing basis.

2.6 Sustainable Supply Chain

Viva Biotech maintains a responsible sourcing strategy and strives to build a resilient and sustainable supply chain that will have a positive impact on the Company, the society and the environment. In the process of procurement and operations, Viva Biotech strictly abides by the laws and regulations of the countries and regions where it operates, including the Law of the People's Republic of China on Bidding and Tendering. The Group has formulated and implemented and regularly updates the Supplier Admission Regulations, the Supplier Management Procedures, the Bidding and Tendering Management System, the Supplier Management System and other relevant policies to maintain clear rules on supplier admission, selection, classification, acceptance inspection, evaluation and management.

2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

2.6.1 Supplier Admission

The Group has established a sound supplier admission system. Pursuant to the Law of the People's Republic of China on Bidding and Tendering, we have established the Bidding and Tendering Management System. We rationalize the whole process of business cooperation under a standardized operation and management model for unified procurement. The system defines full-process management covering selection, classification, acceptance inspection and dynamic evaluation of suppliers, with the aim of building long-term relationships of mutual trust and assistance with partners. In the screening stage, the Procurement Department conducts rigorous qualification review and preliminary screening of potential suppliers based on the admission criteria, and comprehensively evaluates their technical capabilities and commercial reputation based on the multidimensional data collected. To ensure supply stability, we typically select two to three core producers for each item of raw materials, auxiliary materials and packaging materials to establish long-term strategic cooperation. Meanwhile, we provide product standards or samples and conduct sample tests and quotation analysis to ensure technical compliance of suppliers.

In procurement execution, we mainly adopt a competitive tendering model and implement a multi-party supervision mechanism for all procurement contracts through internal audits to ensure the fairness and transparency of the procurement process. In addition, joint departmental approvals are adopted to further avoid procurement risks and protect the Company's interests. The Group implements dynamic management over suppliers. For suppliers with poor performance, fraud, malpractice or integrity issues, we will resolutely blacklist them and notify the Procurement Department that we will not conduct any further transactions with such suppliers, in order to maintain a clean and transparent supply chain environment.

With a commitment to responsible procurement, the Group has set up a separate management department dedicated to the promotion of green supply chain management. With clear and responsible procurement goals in place, we continue to optimize our procurement standards and systems to ensure that the concept of green procurement is integrated into every aspect of the procurement of raw materials, equipment and services. During cooperation, we require suppliers to sign the Procurement Contract that clarify the social responsibilities to be jointly fulfilled. For procurement involving genetically modified ingredients, the supplier shall strictly follow the Administrative Regulations on Safety of Agricultural Genetically Modified Organisms to ensure compliance and safety of the products supplied. Through these initiatives, the Group actively leads and drives the upstream and downstream enterprises in the supply chain to jointly enhance the efficiency of resource and energy utilization, improve environmental performance, and work together to build a sustainable green supply system.



2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

Procurement Management	<ul style="list-style-type: none">• Upstream suppliers shall have certificates of ISO 9001 (Quality Management System), ISO 14001 (Environmental Management System) and ISO 45001 (Occupational Health and Safety Management System)• The products supplied by the supplier must meet the requirements on human and environmental friendliness• Purchase as far as practicable the products that will not consume more energy or generate more waste during use
Green Logistics	<ul style="list-style-type: none">• Prioritize inland suppliers to reduce emissions from long-distance air travel• realize automation with the goal of improving the environmental friendliness of logistic services• achieve effective management of toxic and hazardous materials• promote green recycling and reuse of scrap materials and reagents
Green Packaging	<ul style="list-style-type: none">• Encourage the use of recycled materials labeled as recyclable for packaging materials. If the packaging contains plastic materials, biodegradable materials should be used as much as possible• If polymeric materials are used for packaging, we encourage to use plant fibers and starch-based materials that are non-polluting and renewable
Social Responsibility Related	Supplier are required to undertake in the Procurement Contract to: <ul style="list-style-type: none">• prohibit the use of child labor, prison labor, forced or compulsory labor• provide a safe and healthy working environment, comply with legal provisions on working hours and remuneration, and implement emergency response measures• comply with relevant data protection laws and regulations to safeguard personal information and data security of the Group and users• strictly comply with anti-corruption laws and regulations and oppose any form of corruption and bribery

2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

Case Highlight: ACT Environmental Label

The Group actively monitors ecological footprint of its products. A number of products from suppliers have obtained the ACT environmental label. This label is an international certification promoted by My Green Lab, a non-profit organization, designed to assess environmental impact of laboratory equipment, consumables and chemicals. As verified by our suppliers, it transparently discloses sustainability data of products across sourcing, operation, energy saving and waste disposal.

The ACT label includes an environmental impact scoring system covering the full lifecycle from manufacturing and user operation to end-of-life disposal. A higher score indicates greater environmental impact. This intuitive evaluation system assists the Company in making more eco-friendly choices and enables customers to easily identify and purchase more sustainable products, thus jointly driving green development of the industry.





2. INNOVATION-DRIVEN APPROACH TO SHARED VALUE CREATION

2.6.2 Supplier Evaluation

The Group is committed to building a robust and efficient supply chain system, ensuring business continuity through a strict supplier evaluation mechanism. The Group conducts a comprehensive assessment on key suppliers every year, covering key indicators such as product quality, procurement process, after-sale service, warehouse management and production efficiency. Based on assessment results, suppliers are classified into three tiers i.e. “Core”, “Backup” and “Restricted” for dynamic tiered management. The Group adopts a zero tolerance policy to partners with major quality defects, which will be suspended immediately for cooperation and required to rectify within a specified timeframe, and those with serious malpractices will be permanently expelled, in order to ensure safety and operational efficiency of the supply chain.

For assessment execution, a multi-department joint review team is established to conduct annual comprehensive supplier evaluation in accordance with the Supplier Management Procedures. We assess suppliers’ performance in environmental impact and ESG through various methods such as social responsibility questionnaire and on-site audit. The reviews are jointly performed by procurement, marketing and quality departments by strictly benchmarking against the Supplier Management Procedures and our green supply chain values, to ensure that partners comply with the code of business ethics in protection of employee rights, prohibition of child labor and forced labor, health and safety, and environmental measures. Through dynamic supervision and collaboration, we are committed to working with suppliers to achieve a win-win outcome in social responsibility and business value.

During the Reporting Period, we had a total of 2,119 cooperative suppliers, mainly for raw materials. The suppliers are mainly based in Mainland China, totaling 2,100 suppliers, of which approximately 90% are in East China, 3% in Central China, 5% in North China and 2% in South China. All suppliers are subject to the Group’s supplier engagement and management regulations.

Indicator	2024	2025
Total number of suppliers	2,580	2,119
Mainland China	2,540	2,100
– East China	2,132	1,899
– Central China	202	59
– North China	176	108
– South China and Northeast China	30	34
Overseas	40	19

3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPOWERMENT

Staying at the forefront of biopharmaceutical innovation, Viva Biotech always shoulders a mission of promoting industry progress and improving global health performance. We implement a responsible investment strategy to precisely empower R&D start-ups and accelerate the commercialization of scientific research achievements. The Group is not only a provider of capital and technology, but also a builder of the industrial ecosystem. By strengthening international exchanges and resource integration, we actively break down technological barriers, empower the global biopharmaceutical ecosystem to achieve high-quality sustainable development, and contribute long-term value to human health.

Corresponding UNSDG:




3.1. Responsible Investment

Viva Biotech deeply understands the profound impact of pharmaceutical innovation on human health and firmly implements a responsible investment strategy. Through the Viva BioInnovator (VBI) platform, we provide comprehensive incubation support to promising global biotech start-ups, to accelerate the commercialization of innovative therapies. In full-lifecycle investment management, the Group has established a rigorous due diligence system, deeply participates in decision-making processes of portfolio companies, and fully integrates ESG factors into the evaluation scope. We have defined four core investment strategies, focusing on evaluating the contribution of innovative therapies in eliminating clinical gaps and their market potential. Through these measures, Viva Biotech ensures that it can actively fulfill social responsibilities while generating sound economic return from its investment decisions, thus providing solid support to the health and well-being of patients worldwide.



3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPOWERMENT

Our Four Core Investment Strategies




Professional Post-investment Management and Support

The Group is committed to building an open and shared biopharmaceutical innovation platform, focusing on identification and services in respect of high-value projects worldwide through VBI. We not only provide capital support, but also draw upon the Group’s profound technological expertise and industry experience in new drug R&D to provide portfolio companies with a full spectrum of value-added services including R&D guidance, experimental sites, logistic support, industry partnership, and investment and financing plans.





- **Investment and exit:** As at December 31, 2025, the Group had invested in a total of 93 portfolio companies. During the Reporting Period, we realized proceeds of approximately RMB83.6 million through strategic exits from several portfolio companies. So far, we have completed exit from a total of 19 portfolio companies. In addition, the Company has received proceeds from disposal of incubation portfolio companies of approximately RMB205.1 million after the Reporting Period. Furthermore, the Company intends to use part of such exit proceeds to fully leverage its existing AI+SBDD dry and wet laboratory platform for incubation of the Group’s proprietary pipelines.
- **Financing and R&D:** During the Reporting Period, 13 incubated portfolio companies achieved breakthroughs in fundraising, and raised total proceeds of US\$453.3 million. Their total R&D pipelines increased to 231, of which 44 have entered clinical stages, representing an increasing proportion.

3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPowerMENT





3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPOWERMENT

Overview of companies partnering with or empowered by us	
	Ophidion entered into a strategic partnership with Neuronasal to develop therapies for Parkinson’s disease, obesity and diabetes via a novel CNS delivery platform
	ArthroSi reached an agreement with Sobi for acquisition at US\$1,500.0 million, following a US\$153.0 million Series E funding round. Its core product Pozdeutinurad completed phase III clinical patient enrollment
	Proviva Therapeutics closed Series A+ funding round of over US\$30 million, and is advancing clinical development of PTX-912, a global first-in-class PD-1/IL-2 prodrug fusion protein
	Apeiron Bio announced phase I first-in-human data for GTA182 at 2025 ESMO ASIA
	Domain initiated phase I/II clinical trials on DT-7012 targeting CCR8 for solid tumors, and dosed the first batch of patients
	Basking dosed the first batch of patients in Part B of a phase II clinical trial, unlocking a US\$27.5 million financing tranche
	AmacaThera signed a global exclusive license agreement with Pacira worth up to US\$230.0 million, and collaborated with Merck Animal Health in animal health

3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPOWERMENT

Overview of companies partnering with or empowered by us	
	United InnoMed closed a funding round of over RMB100 million. Its NOVAtria® system debuted at ESC 2025
	AceLink reported positive top-line results from a phase 2 study of AL01211 in male patients with classic Fabry disease
	VivaVision closed Series D2+ funding round of over RMB100 million. Its VVN461 eye drop (having received a CDE breakthrough therapy designation) and VVN1901 eye drop have completed the first-patient-in respectively for phase III and phase II clinical trials in China
	QureBio closed a RMB100 million Series C funding round, and is accelerating clinical progress of its core pipeline
	HAYA closed a US\$65 million Series A funding round, and is developing precision RNA-guided therapies
	Grove closed a US\$30 million Series A funding round, and is developing Bionic Biologics, a novel drug modality
	Genhouse Bio's PRMT5 inhibitor GH56 was approved for clinical trial by NMPA and FDA
	Mediar reach a partnership of up to US\$786.0 million with Eli Lilly to advance WISP1, a first-in-class antibody for treatment of IPF
	TechnoDerma completed phase IIa clinical trial of TDM-180935 in the United States for atopic dermatitis



3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPOWERMENT

3.2. Promoting Industry Cooperation

Adhering to dual drivers of technological innovation and strategic cooperation, Viva Biotech remains committed to building a full-spectrum integrated service system covering R&D, production and collaboration. We deepen industry engagement by hosting high-profile forums and actively participating in international academic conferences, showcasing the Group's outstanding professional capabilities and forward-looking global presence to the world. Meanwhile, we maintain in-depth dialogues with top global experts, lead discussions on industry standards and frontier trends, and strive to foster a mutually beneficial industrial ecosystem. By continuously deepening R&D collaboration with global partners, the Group injects strong momentum into sustainable growth of the biopharmaceutical industry to fulfill its firm commitment to promoting progress across the industry. During the Year, we organized over 20 domestic and 50 overseas exchange events, demonstrating our strategic footprint of deepening industry cooperation and efforts to build a global win-win ecosystem.

3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPOWERMENT

Case Highlight: SAPA-China 2025 pharmaceutical industry conference

At the SAPA-China 2025 pharmaceutical industry conference, Dr. Ma Jianguo, Senior Vice President, and Dr. Qian Yue, Executive Officer of Computational Chemistry and AI Platform of the Group, were invited to share their insights.

In her presentation titled “AI-enabled Peptide Drug Design”, Dr. Qian Yue introduced in detail Viva Biotech’s computational methodologies in peptide R&D. Using practical examples, she illustrated how five core elements, i.e. high-performance computing, foundational large models, data, algorithms and structural biology, are organically integrated to form a complete technical system.

Dr. Ma Jianguo focused on “API Development – China’s Path from Generics to Innovative Drugs”, reviewing the evolution and policy development of China’s pharmaceutical industry in generics and innovative drug APIs, and analyzing key R&D considerations for innovative drug APIs from phase I, II, III clinical trials to NDA submission. Through such high-level academic sharing, the Group not only demonstrated its profound technological expertise but also contributed insights to the common progress of the industry.





3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPOWERMENT

Case Highlight: The 10th Guangzhou (Greater Bay Area) Summit for Biopharma Innovators

Viva Biotech participated in the 10th Guangzhou Summit for Biopharma Innovators for 2025. Dr. Cai Jianhua, Senior Vice President, and Dr. Deng Xinyu, Vice President of Biologics, shared our practices and insights on “AI-enabled XDC” and “Breakthrough Pathways for China’s Innovative Drugs”, respectively.

Dr. Deng Xinyu highlighted Viva Biotech’s exceptional organizational synergy: the Company’s macromolecule, micromolecule, peptide and computational design teams are all based at its Shanghai headquarters, with over 1,000 employees collaborating efficiently across disciplines. To date, the team has accumulated over 3,000 programs in PDC (peptide-drug conjugate) and RDC (radionuclide-drug conjugate), and successfully delivered several high-difficulty AOC (antibody-oligonucleotide conjugate) programs.

In a panel discussion, Dr. Cai Jianhua noted that China’s innovative drug ecosystem boasts unique advantages spanning from upstream biotechs and investors, midstream full-chain CRO services, to downstream CMC, CDMO and mature clinical systems. Viva Biotech deeply engages in R&D innovation through the EFS model, participating throughout the process from early screening to clinical development, leveraging its complete ecological closed loop to help Chinese companies achieve rapid innovation.



3. INDUSTRY LEADERSHIP AND MULTI-DIMENSION EMPOWERMENT

3.3. Empowering Industry Development

Upholding its corporate mission, the Group deeply integrates social responsibility into its development strategy to fully empower the industrial ecosystem. Through optimized resource allocation and external collaboration, we provide in-depth technology and capital support to portfolio companies, driving innovative breakthroughs in frontier fields including biopharmaceuticals and digital health, with the aim of improving the accessibility of global healthcare services. As of the end of the Reporting Period, the Group had successfully completed full or partial exits cumulatively from 19 portfolio companies with related proceeds to be continuously reinvested in the Company's strategic blueprint. This virtuous cycle not only strengthens the Group's sustainable development capacity but also demonstrates our firm commitment to the social health cause.

Case Highlight: Viva Biotech Participates in Establishing a Venture Capital Fund to Build a Collaborative Industrial Ecosystem

Actively practicing the concept of responsible investment, the Group jointly established a RMB300.0 million venture capital fund with multiple investment institutions, where Hangzhou Viva Zongchen (a wholly-owned subsidiary of the Company) expects to invest RMB25.0 million, representing 8% of capital contribution. Focusing on early-stage pharmaceutical development programs, the fund has a key emphasis on cutting-edge technological innovation and commercialization in life sciences, and is dedicated to identifying and incubating innovative pharmaceutical companies with core technological strengths and market potential.

By providing critical capital support to early-stage projects, the fund builds an efficient bridge between local industrial clusters and innovative enterprises, effectively promoting the formation of a virtuous industrial eco-cycle. The joint establishment of the fund not only enhances the Group's visibility of cutting-edge technological dynamics and market trends, but also creates greater opportunities for exploring innovative mechanisms complementary to the EFS investment and incubation model. It not only broadens the headroom for in-depth cooperation between the Company and potential strategic partners, but also demonstrates the Group's long-term commitment to empowering industry innovation through capital. Currently, the fund has entered normal operation following the completion of its initiation and establishment.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

As a key player in the global biopharmaceutical industry, Viva Biotech regards environmental benefits as an integral part of its core value. Guided by green operation, we are committed to achieving low-carbon and sustainable development, taking environmental initiatives in resource management, waste treatment and climate change response to publicize the green concept. By establishing an efficient and scientific environmental management system, we continuously improve resource utilization efficiency, explore the application of clean energy, and strictly comply with environmental laws and regulations, to actively meet expectations and standards of the industry and society on sustainable development.

Corresponding UNSDGs:



4.1. Supporting the Climate Actions

The Group demonstrates a profound understanding of the challenges posed by climate risk and attaches paramount importance to its potential impact on the business ecosystem. We strictly adhere to the requirements under the ESG Reporting Code of the Hong Kong Stock Exchange, with reference to the IFRS Sustainability Disclosure Standards IFRS S2 issued by the International Sustainability Standards Board (ISSB). We have systematically established a climate risk management framework across four core pillars: governance, strategy, risk management, and metrics and targets. Through proactive implementation of improvement initiatives, the Group continuously enhances its capacity to manage physical risks and transition risks, and develops industry-specific response strategies to materially strengthen corporate climate resilience. We are committed to pursuing sustainable operations while contributing to the building of a climate-friendly society.

Climate Governance

To effectively address the challenges posed by climate change, the Company has deeply integrated climate governance into its existing ESG organizational structure. The Board, together with the Audit Committee, exercises the ultimate governance authority and retains full decision-making power over all climate-related matters. The ESG senior management assumes overall responsibility for the oversight and stewardship of climate-related strategies, with core mandates encompassing the identification of inherent climate-related risks and opportunities, the assessment of climate change impacts, as well as the ongoing review of the establishment and delivery progress of climate-related targets. Furthermore, the ESG Working Group comprising functional leads conducts regular in-depth deliberations and updates on prevailing climate risks and opportunities, policy dynamics and industry best practices. For detailed responsibilities, please refer to the section headed “ESG Governance Structure”.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Climate Strategy

The Group has implemented a sophisticated framework for risk identification and opportunity management. Through science-based preventive measures and strategic deployment, we proactively manage climate-related risks to effectively mitigate their adverse implications for the Group's sustainable development, while pursuing transformative opportunities amid global shifts to deliver long-term value for shareholders.

During the Year, we have further identified the impact timeframes of diverse climate-related risks. Such risks are assessed across three distinct horizons: short-term (within 3 years), medium-term (3 to 6 years) and long-term (over 6 years). To date, we have identified a total of five climate risks (comprising three transition risks and two physical risks) together with one climate opportunity. This enables us to proactively seize the momentum of green transition and foster the development of more climate-resilient communities and society at large.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Risks	Aspect	Description of risk/opportunity	Potential financial impact	Time horizon of impact	Our actions
Physical risks	Acute physical risks	Frequent occurrence of extreme weather events (e.g., typhoons, rainstorms, floods, etc.) may affect the safety of the Company's buildings and equipment, lengthen the commuting time of employees, and have certain impacts on the safety of employees and the normal operation of the Company	<ul style="list-style-type: none"> • Increase in operating costs • Increase in employee insurance and subsidies • Decrease in revenue 	Medium- to short-term	<p>At the operational level, we have enhanced disaster-resistant design for buildings, deployed water-proofing and flood-control facilities, and installed backup power generation systems. We have established contingency plans for extreme weather events and implemented flexible working arrangements to safeguard employee safety and ensure uninterrupted operation of core equipment, while coordinating responses with local emergency authorities. Our sites located in coastal areas have adopted design measures including foundation elevation during construction to mitigate the impacts of heavy rainfall and flooding</p> <p>In respect of the value chain, the Group has formulated inventory preparedness plans for natural disasters. We diversify disaster-related risks by engaging suppliers with geographically dispersed production bases and prioritizing local suppliers, thereby minimizing disruptions to the supply chain arising from extreme weather events</p>
	Chronic physical risks	<p>Sustained high temperatures due to global warming may increase the energy consumption of the Company's cooling equipment (e.g., air conditioners)</p> <p>Sustained high temperatures may also cause problems with the quality of drugs during transportation and storage</p>	<ul style="list-style-type: none"> • Increase in operating costs 	Long-term	<p>Upgrade to efficient refrigeration equipment, introduce intelligent temperature control system and photovoltaic energy storage technology, and optimize energy consumption of laboratory environment; Regularly maintain equipment performance, renovate buildings with insulation materials, and reduce the long-term dependence of heat load on energy</p> <p>Regularly review the process and condition of drug storage to ensure that the temperature does not affect the quality of the drugs</p>

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Risks	Aspect	Description of risk/opportunity	Potential financial impact	Time horizon of impact	Our actions
Transitional risks	Policies and Regulations	Changes in climate change-related policies, both domestically and internationally, may result in additional costs for the Company to ensure compliance	<ul style="list-style-type: none"> Increase in compliance costs 	Medium-to short-term	Establish a compliance monitoring team to dynamically track domestic and international climate policies, deploy low-carbon technology R&D in advance, regularly evaluate the impact of policy and regulatory risks on enterprises, and develop the corresponding risk response strategy
	Market	As public awareness of sustainability grows, investors and consumers may demand more on animal rights, natural and organic medical products. If the Group's products are perceived as violating animal rights or being less sustainable than alternatives, a decline in demand may occur	<ul style="list-style-type: none"> Increase in operating costs Decrease in revenue 	Long-to medium-term	The Group operates a stringent quality control and assessment system to ensure that all pharmaceutical products are free from animal rights violations or genotoxic and genetically modified plants Establish a regular market analysis mechanism, strengthen trend tracking, optimize supply chain management, and timely grasp market dynamics
	Reputation	Failure of the Company in fulfilling its social responsibility to take appropriate measures to manage the potential impacts of climate change may affect the perception of the Company by various stakeholders, including investors	<ul style="list-style-type: none"> Damage to corporate image Reduced investment 	Long-term	Develop a carbon neutrality roadmap and set short-term emission reduction targets, incorporate a third-party sustainability rating system, and enhance stakeholder trust through transparent disclosure of our climate action results and continuous communication with stakeholders to understand their concerns and needs In addition, Langhua Pharmaceutical discloses its own climate-related information on the Carbon Disclosure Project (CDP) platform to enhance information transparency



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Risks	Aspect	Description of risk/opportunity	Potential financial impact	Time horizon of impact	Our actions
Opportunity	Product	As climate change may indirectly affect public health, the demand for products and services related to monitoring and mitigating environmental health risks is likely to increase. Viva Biotech may expand into new markets with products that meet these needs	<ul style="list-style-type: none"> Increase in revenue 	Long-term	The Group actively employs the EFS investment and incubation business model to identify and nurture promising drug research and development companies, jointly exploring the biopharmaceutical market and achieving sustainable development

Climate Risk Management

The Group has instituted a sophisticated ESG Materiality Issue Indicator Management Process, establishing a rigorous oversight and internal control regime for material ESG issues and their associated risks, encompassing climate-related risks. In the course of risk assessment, we holistically evaluate the probability of risk incidence and its magnitude of financial and operational implications to deliver evidence-based risk categorization, thereby ensuring the rigor and forward-thinking orientation of risk management activities. To uphold the quality of governance, the Internal Audit Department conducts annual dedicated reviews on information pertaining to material ESG issues, including climate-related data, to critically identify key areas for improvement in the implementation of ESG policies and measures. During the Reporting Period, no material climate-related risks were identified, and the risk management framework remained unchanged notwithstanding the identification of additional climate risks.

To effectively address extreme weather events arising from physical risks, all of the Group’s parks have formulated the Emergency Response Plan for Sudden Environmental Incidents tailored to their respective operational contexts, which aims to prevent accidental environmental pollution incidents and maximize the protection of employees’ life, health and property safety in the event of an incident. Developed in strict compliance with the requirements set out in the Risk Classification Methods for Enterprise Sudden Environmental Incidents, the plan incorporates risk classification and assessment specifically for extreme weather events. It comprehensively covers monitoring preparedness, early warning protocols, response measures and evacuation arrangements for natural disasters including flood prevention and control.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

To ensure the efficacy of the emergency response plan, the Group systematically reviews and evaluates environmental risks, preparedness deficiencies, emergency command structures, and equipment readiness across all parks. Plans are revised and updated in a timely manner in line with operational requirements. Concurrently, all parks conduct annual climate disaster preparedness training to deepen employees' comprehension of climate-related hazards, enhance proficiency in disaster prevention and response, and collectively fortify the Group's operational safety framework. Additionally, the Group has obtained environmental pollution liability insurance and comprehensive property insurance to deploy financial mechanisms for risk transfer, thereby materially mitigating potential financial shocks from climate disasters and further strengthening the Group's risk and operational resilience.

Climate Metrics and Targets

The Group actively aligns with the temperature control objectives of the Paris Agreement and China's "3060 Dual Carbon Goals", establishing definitive climate-related operational targets. Through the implementation of energy conservation and emission reduction strategies, coupled with green office initiatives, the Group is committed to systematically lowering operational carbon emissions across its CRO and CDMO segments. The low-carbon philosophy is fully embedded throughout the entire business lifecycle.

Among the Group's business segments, the pharmaceutical manufacturing process within the CDMO segment (Langhua Pharmaceutical) constitutes the primary source of carbon emissions. In response, Langhua Pharmaceutical has formulated distinct and comprehensive near-term emission reduction targets, which have been formally validated by the Science Based Targets initiative (SBTi). By instituting a decarbonization strategy consistent with the global 1.5°C temperature control pathway, we maintain profound alignment between the Company's operations and the goals of the Paris Agreement. Historically, the Group established phased environmental objectives targeted for 2025, focused on water resource management and non-hazardous waste minimization. During the Reporting Period, all predefined targets were fully achieved through disciplined and effective resource management measures.

Type	Legacy Targets	Achievement
Water resources	Water consumption per RMB10,000 of output in 2025 shall be reduced by 25% compared to the 2020 base year	✓ Water consumption intensity per RMB10,000 of output reduced by 63% compared to the base year, representing full achievement
Non-hazardous waste	Non-hazardous waste generated per RMB10,000 of output in 2025 shall be reduced by 50% compared to the 2020 base year	✓ Non-hazardous waste intensity per RMB10,000 of output reduced by 61% compared to base year, representing full achievement



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

During the Year, we established an updated set of environmental targets covering water consumption, non-hazardous waste generation, and energy consumption to more effectively support the attainment of near-term emission reduction objectives.

Type	Target	Target year	Progress in 2025
Carbon emission	Relative to the 2023 base year, absolute carbon emissions (including Scope 1 and Scope 2) shall be reduced by 42%	2030	○ Relative to the base year, absolute greenhouse gas emission for Scope 1 and Scope 2 decreased by 17%
	Relative to the 2023 base year, carbon emission intensity per RMB10,000 output (including Scope 3) shall be reduced by 52%	2030	○ Relative to the base year, greenhouse gas emission intensity for Scope 3 decreased by 5% ¹
Water resources	Relative to the 2023 base year, water consumption per RMB10,000 output shall be reduced by 25%	2030	① Relative to the base year, water consumption per RMB10,000 output increased by 64% ²
Solid waste	Relative to the 2023 base year, solid waste generation per RMB10,000 output shall be reduced by 50%	2030	○ Relative to the base year, solid waste generation decreased by 19%
Energy	Relative to the 2023 base year, energy consumption per RMB10,000 output shall be reduced by 40%	2030	① Relative to the base year, energy consumption per RMB10,000 output increased by 17% ²

○ On track; ① Lagging behind

¹ As certain data under scope 3 have not been applied, the status against target herein only includes categories 1, 2 and 3.

² Owing to production increase and revenue decrease in the Year, there was a rise in water and energy consumption per RMB10,000 industrial output value. We have formulated a series of water-saving and energy conservation plans, which will be gradually implemented in the coming years to ensure the attainment of the targets.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

While the carbon emission intensity of the CRO business is lower than that of the CDMO business, the Group has nonetheless established clear targets for energy conservation and waste reduction. This demonstrates its commitment to full value chain decarbonization, effectively advancing the implementation and enhancement of relevant environmental management measures and driving continuous improvement in resource efficiency across all operations. The Group actively promotes environmental awareness and waste reduction initiatives, achieving notable progress in waste management. Through full employee participation and process optimization, we reduced non-hazardous waste by more than 0.3 metric tons during the Year, successfully meeting the annual non-hazardous waste reduction target. Driven by increased research and laboratory activities, hazardous waste generation rose slightly during the Year. In response, we are conducting a comprehensive review of related laboratory and operational procedures to identify potential reduction areas and optimization opportunities. Moving forward, we will continue to refine waste management controls, support business growth while striving to minimize our environmental footprint, and ensure steady progress toward all environmental targets.

2026 Environmental Targets

Type	2026 targets
Electricity	Shanghai and Jiaxing Viva Parks: Maintain total electricity consumption within a 5% fluctuation range compared with 2025
Solid Waste	Non-hazardous waste: Reduce non-hazardous waste by 0.45 tons
	Hazardous waste: Reduce hazardous waste by 6 tons
Packaging Materials	Reduce packaging materials by 0.35 tons

The Group has established a robust environmental target monitoring mechanism. Through regular oversight of key environmental indicators and close progress tracking, it ensures the steady achievement of all established objectives. For details on key environmental performance indicators (KPIs), please refer to the relevant tables in section “4.2 Energy Conservation and Emission Reduction Actions and Measures”. To date, the Group has not integrated climate-related indicators into its remuneration and incentive system, nor has it adopted an internal carbon pricing strategy. Going forward, we will continue to monitor industry trends and actively explore the feasibility of relevant policies to further drive the Group’s green and low-carbon transition.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

4.2. Energy Conservation and Emission Reduction Actions and Measures

4.2.1 Environmental Management Approach

To advance the integration of sustainable development and environmental conservation, the Group has instituted a sophisticated environmental management system. We uphold full adherence to the Environmental Protection Law of the People's Republic of China and an extensive suite of environmental laws, regulations and industry standards, and have enacted internal governance documents including the Environmental Protection Management Rules and the Environmental Aspects Identification and Assessment Procedure. These governance provisions codify core environmental principles and accountability structures across all tiers, encompassing the full spectrum of environmental management considerations throughout production and operations. No material non-compliance with environmental laws and regulations was identified during the Reporting Period.

In operational execution, the Group evaluates and manages significant environmental aspects and proactively drives the implementation of improvement initiatives to address potential environmental risks with precision. We have established a dedicated Environment, Health and Safety (EHS) department with overall responsibility for emissions management, efficient resource utilization and pollution prevention, ensuring strict adherence to all environmental performance standards. In addition, the Group has issued the Energy Conservation and Emission Reduction Initiative and the Green Office Initiative, vigorously advancing green office practices, encouraging employee participation in energy and resource conservation, and fostering an environmentally responsible workplace. Concurrently, we deliver environmental awareness training through multiple channels to strengthen sustainability mindset across the Group.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

With respect to the CDMO business segment, we have formulated the Greenhouse Gas Inventory Management Procedure. Led by the General Manager, a dedicated GHG Inventory Task Force has been established to conduct regular greenhouse gas inventories and prepare corresponding reports. The structure and responsibilities of the GHG Inventory Task Force are as follows:

Top Executive Officer (General Manager)	<ul style="list-style-type: none"> • Approve the establishment of the GHG Inventory Task Force and appoint its team leader • Provide necessary resources and support for the implementation of greenhouse gas inventory activities • Approve the audited inventory list and inventory report
Task Force Leader (Head of Engineering & EHS Department)	<ul style="list-style-type: none"> • Define organizational and reporting boundaries • Formulate and dynamically track the inventory progress plan • Review the inventory list and inventory report • Govern and maintain relevant inventory files and data
Task Force Members (Staff from relevant departments)	<ul style="list-style-type: none"> • Collect data and calculate emissions • Compile inventory lists and inventory reports

During the Year, Langhua Pharmaceutical successfully obtained the ISO 14001 environmental management system certification and achieved a low-risk rating in the ESG module audit conducted by the Pharmaceutical Supply Chain Initiative (PSCI). These achievements demonstrate that the Group has established a comprehensive and mature environmental management system, laying a solid foundation for the attainment of its environmental targets

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Langhua Pharmaceutical was recognized as a Municipal Green and Low-Carbon Factory

Langhua Pharmaceutical has been duly conferred the honorary title of “2025 Taizhou Municipal Green and Low-Carbon Factory” by the People’s Government of Taizhou Municipality. This prestigious accolade serves as official recognition of the Company’s sustained investment and innovative practices in green manufacturing, as well as the natural outcome of its unwavering commitment to the strategy of “ecological priority, green development”. Langhua Pharmaceutical has continuously upgraded and optimized its production processes, three-waste treatment, energy conservation and consumption reduction across all operational aspects. Going forward, Langhua Pharmaceutical will further escalate investment in green technology R&D, deepen integrated innovation between digital governance and low-carbon production, steadily improve resource utilization efficiency, and contribute to the national “dual carbon” goals through concrete actions.

浙江省台州市经济和信息化局

关于 2025 年台州市市级绿色低碳工业园区、工厂名单的公示

根据台州市经济和信息化局《关于印发 2025 年台州市绿色制造工作要点的通知》（台经信〔2025〕54 号）和台州市经济和信息化局《关于印发台州市绿色低碳工业园区、工厂建设评价导则（2025 版）的通知》（台经信〔2025〕15 号）文件要求，经企业自愿申报、各县（市、区）初审推荐，经专家综合评审，初步确定 2 家工业园区为 2025 年度台州市市级绿色低碳工业园区、169 家企业为 2025 年度台州市市级绿色低碳工厂。现予以公示，公示期 10 天（从 2025 年 11 月 28 日至 2025 年 12 月 7 日）。如有异议，请署真实姓名及联系地址，以书面形式于 2025 年 12 月 7 日以前向市经信局反映。

联系电话：0576-88510350
地址：台州市行政中心 5 号楼 台州市经济和信息化局高端装备与新材料处

序号	工厂名称
30	科马斯龙动力机械有限公司
31	台州福莱生态环保科技有限公司
32	浙江万盛股份有限公司
33	浙江东大新能源材料有限公司
34	浙江明华制药有限公司
35	浙江天和树胶有限公司
36	泰利莱（台州）药业有限公司
37	台州世达汽车零部件有限公司
38	浙江创为真空设备股份有限公司
39	临海市四通制管有限公司
40	浙江伟星光学股份有限公司
41	盛昌集团有限公司
42	浙江大豪车业有限公司
43	双马铝业有限公司
44	临海宇城发绿色装配式建筑制造有限公司
45	浙江飞捷机电有限公司

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

4.2.2 CDMO Carbon Emission Reduction Roadmap

The Group has developed a comprehensive and well-defined carbon emission reduction roadmap, committing to a 42% absolute reduction in Scope 1 and Scope 2 greenhouse gas emissions by 2030 relative to the base year. Its strategic vision extends well beyond 2030, with a forward-looking perspective up to 2050, aspiring to achieve planned net-zero emission targets through sustained long-term efforts.

To ensure the attainment of emission reduction targets, the Group's decarbonization strategy is structured around three distinct phases and four key initiatives for emissions reduction.

Three Distinct Phases	<p>Prior to 2028: Initial emission reductions will be achieved primarily through on-site energy conservation, consumption reduction and energy substitution measures, coupled with the commencement of green electricity procurement deployment.</p> <hr/> <p>2028-2035: Gradually introduce and scale up the proportion of renewable energy such as green steam.</p> <hr/> <p>Post-2035: As the contribution from energy conservation and consumption reduction plateaus, deep decarbonization will be attained through minimizing liquid waste discharge, large-scale procurement of green energy, and deployment of cutting-edge green and renewable energy technologies.</p>
Four Key Emission Reduction Initiatives	<p>Reduce Energy Demand: Priority shall be given to upgrading existing equipment to more efficient and lower-emission alternatives, while continuously optimizing production processes to enhance energy efficiency in manufacturing operations.</p> <hr/> <p>Electrification Transformation: Where technically feasible, replace all fossil fuel-powered equipment with electric-driven equipment as much as possible.</p> <hr/> <p>Renewable Energy Self-Sufficiency: Install photovoltaic panels on-site to supply on-site renewable energy and directly reduce Scope 2 emissions.</p> <hr/> <p>Green Electricity Procurement: For essential electricity consumption not satisfied by self-generated renewable energy, ensure the achievement of renewable energy utilization targets through measures including the purchase of Renewable Energy Certificates (RECs).</p>



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

For Scope 3 emissions, Langhua Pharmaceutical commits to reducing its greenhouse gas emission intensity per RMB10,000 revenue by 52% by 2030 relative to the base year. Within the emission profile of Langhua Pharmaceutical, Scope 3 emissions predominantly stem from Category 1: Purchased Goods and Services and Category 2: Capital Goods. To deliver on emission reduction objectives, Langhua Pharmaceutical primarily adopts raw material minimization strategies and procures sustainable chemicals to curtail supply chain carbon footprint at source. Concurrently, it reduces emissions across all other operations by optimizing internal management, enhancing packaging waste recovery, and advancing green logistics and low-carbon mobility. Langhua Pharmaceutical will sustain in-depth collaboration with upstream and downstream value chain partners, proactively identify and harness additional decarbonization opportunities, and endeavor to establish a more robust and sustainable low-carbon value chain.

Langhua Pharmaceutical plans to conduct carbon footprint life cycle assessments for selected core products. Through in-depth whole-life-cycle analysis, it will scientifically unlock further decarbonization potential within Scope 3, laying a solid foundation for the low-carbon transition of the entire value chain.

4.2.3 Green Operation

Viva Biotech is committed to integrating environmental stewardship into its operational practices, mitigating greenhouse gas emissions through refined management, and advancing green pharmaceutical manufacturing. The Company has established a comprehensive energy management system covering procurement, production and performance evaluation, consisting of multiple policies including the Energy and Resource Management Procedure, Energy Procurement and Approval Management System, Energy Production Management System, and Energy Performance Assessment, Reward and Punishment System, thereby ensuring efficient energy utilization. The Company regularly conducts energy efficiency audits and proposes equipment optimization proposals at quarterly environmental, health and safety meetings to fulfill its commitments to energy conservation and consumption reduction.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Last year, the Shanghai Park engaged the Shanghai Chemical Industry Environmental Monitoring Station to conduct a cleaner production audit and assessment, with the formal audit report released in 2025. The audit covered multiple core dimensions, including corporate development and surrounding environmental risks, process management, energy and resource management, emissions management, as well as solid waste and hazardous waste management. Based on thorough investigation and analysis of the Company's overall operations, a systematic evaluation was conducted on the cleaner production elements and overall performance of the Park. The results indicated that the vast majority of operational activities at the Park fully met cleaner production requirements. For individual non-conformities identified during the audit, the Group completed rectification promptly to ensure high-standard compliance in all production activities.

Furthermore, the report provided an in-depth analysis of cleaner production potential, exploring the root causes of energy consumption across process, equipment, management, product and employee behavior dimensions, and accordingly put forward targeted improvement recommendations. In 2025, we fully adopted and implemented all recommendations from the auditing experts. By further optimizing management processes and upgrading equipment for energy conservation, water efficiency, and waste reduction, we significantly enhanced resource utilization efficiency. The audit not only validated the effectiveness of green operations at the Shanghai Park but also provided scientific guidance and practical impetus for the Group to continuously deepen its energy-saving and emission-reduction efforts.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Langhua Pharmaceutical further strengthened its responsibility system through the Energy Conservation Plan, and implemented dynamic management with rolling adjustments via regular meetings, ensuring that all energy-conservation policies evolve in step with the times, thereby comprehensively enhancing energy efficiency and advancing toward the goal of green pharmaceutical manufacturing.

Energy conservation and carbon reduction measures in the Year

Category in energy efficiency & decarbonization	Scope of business	Description of measures
Renewable energy	CRO	<ul style="list-style-type: none"> During the Year, we have completed the installation of solar photovoltaic panels at the carport of the Shanghai Park, which supply power for the charging of vehicles and electric bicycles, as well as for the lighting system of the carport. The total cost of the project amounted to approximately RMB80,000. To date, the cumulative power generation of the photovoltaic panels has reached 9,010.1 kWh.
	CDMO	<ul style="list-style-type: none"> During the Year, photovoltaic panels have been installed on the factory rooftops, with a total photovoltaic power generation of 91,905.4 kWh, equivalent to a carbon dioxide emission reduction of 47.4 tonnes.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Category in energy efficiency & decarbonization	Scope of business	Description of measures
Optimization of equipment energy efficiency	CRO	<ul style="list-style-type: none"> • Peristaltic Pump Efficiency Retrofit: Technical optimization has been deployed to curtail the operating power rating of peristaltic pumps and mitigate electrical energy consumption. • Centrifuge Efficiency Retrofit: The legacy equipment was upgraded to high-capacity refrigerated centrifuges. The increase in single-batch processing capacity reduces operational frequency and shortens runtime, thereby delivering substantial curtailment in energy consumption. • Drying Unit Efficiency Retrofit: Lower-power vacuum drying ovens have been introduced to optimize drying efficiency, meeting production requirements within a shorter operating cycle and achieving tangible decarbonization and energy optimization.
	CDMO	<ul style="list-style-type: none"> • Comprehensive optimization of the steam system has been conducted, including upgrading steam traps, installing automatic steam pressure regulation devices and refining production operation procedures, effectively lowering the steam loss rate. In the Year, a total of approximately 1,200 tons of steam was conserved. • In the Year, all purchased equipment including dehumidifiers and air conditioners has been replaced with high-efficiency alternatives, ensuring such equipment meets the Level 2 or higher energy efficiency standard. • Optimization has been performed on the circulating water pump system, yielding an estimated annual electricity reduction of approximately 14,000 kWh. • A new three-chamber regenerative thermal oxidizer (RTO) has been installed. Waste heat recovery minimizes fuel consumption and enhances the overall efficacy of energy optimization and emission abatement.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Category in energy efficiency & decarbonization	Scope of business	Description of measures
Energy and process stewardship	CRO	<ul style="list-style-type: none"> • Laboratory Integration and Optimization: The chemical and pharmaceutical R&D laboratory has been reorganized, with experimental activities centralized to substantially enhance fume hood utilization efficiency and effectively mitigate energy waste arising from vacant space. • Oven Parameter Optimization: Fine-tuning has been implemented for oven operating parameters, reducing equipment operational load while ensuring process quality, thereby achieving electricity conservation. • Purified Water Generation Operation Optimization: Scientifically structured scheduling for purified water production minimizes non-productive runtime of water purification systems and curtails electrical energy depletion. • Compound Design Pathway Optimization: Green reaction pathways featuring high atom economy and low solvent toxicity are prioritized in the design of compound synthesis routes.
	CDMO	<ul style="list-style-type: none"> • Waste Heat Recovery and Reutilization: High-temperature flue gas from the waste liquid furnace is directed to a waste heat boiler to recover waste heat for generating saturated steam, which is used for equipment operation and on-site utility supply. • Waste heat is recovered and reused in the waste liquid incineration system to generate steam for the Company's production operations, achieving substantial steam conservation.
Phase-out and replacement of high-emission equipment	CRO	<ul style="list-style-type: none"> • Existing diesel-powered forklifts, commercial vehicles and group shuttle buses are being gradually replaced with new energy vehicles. • Key equipment such as low-temperature coolant circulation pumps has been upgraded to high-efficiency models with lower power ratings, thereby reducing the carbon footprint inherent in operations at the source.
	CDMO	<ul style="list-style-type: none"> • Phase-out of all China II standard internal combustion forklifts across the plant is underway, with electric forklifts being progressively introduced.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION


Category in energy efficiency & decarbonization	Scope of business	Description of measures
Promotion of green efficiency and sustainability	CRO	<ul style="list-style-type: none"> • Strict temperature controls are imposed: a maximum of 20°C in winter and a minimum of 26°C in summer, thereby curbing energy consumption. • Intensified inspections and monitoring have been implemented across laboratories to ensure timely energy shutdown of idle equipment, with appropriate measures imposed for non-compliance. • Regular notifications and training programs on energy and water stewardship are provided to employees on a periodic basis.
	CDMO	<ul style="list-style-type: none"> • Vehicle deployment is rationally arranged to minimize total vehicle mileage. • Regular notifications and training programs on energy and water stewardship are provided to employees on a periodic basis.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION



Integrated PV, Energy Storage and Charging System for Carports



Energy-Saving Retrofit of Drying Units



Waste Heat Recovery and Reutilization



Laboratory Integration and Optimization



Energy-Saving Retrofit of Peristaltic Pumps




Class 2 Energy-Efficient Dehumidifier

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Scope 3 emission reduction measures

The primary task of reducing Scope 3 emissions is to accurately identify and quantify the carbon footprint across the value chain. Following last year's initial attempt to disclose selected Scope 3 categories, the Group further enhanced verification efforts during the Year and conducted a comprehensive assessment of all applicable categories. This initiative aims to precisely identify emission hotspots, thereby enabling more systematic evaluation and management of carbon emission impacts along upstream and downstream supply chains. We adopted methodologies consistent with the greenhouse gas accounting framework, and focused on collecting GHG data for Categories 1, 2, 3, 4, 5, 6, 7 and 9. Other categories are either non-applicable or of relatively low significance and will be refined and improved step by step in the future. Based on in-depth analysis, we identified Category 1: Purchased Goods and Services as the largest source of the Group's Scope 3 emissions, accounting for approximately 61% of total Scope 3 emissions. In light of the verification results, we have formally included emission data for Category 1: Purchased Goods and Services and Category 2: Capital Goods in this Year's report to present a clearer picture of the Group's emission profile.

Scope 3 Carbon Emission Profile of Viva Biotech³



³ The following charts cover Scope 3 categories 1, 2, 3, 4, 5, 6, 7 and 9. For data completeness and accuracy, we will only disclose data for categories 1, 2, 5 and 6.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

To effectively reduce Scope 3 emissions, we have developed and implemented a series of targeted measures. As purchased goods and services represent our primary Scope 3 emission hotspot, we actively seek and prioritize the procurement of eco-friendly raw and auxiliary materials as well as low-carbon products. We also encourage and support the preferential purchase of services and products from domestic or neighboring regions to reduce the carbon footprint in logistics by shortening transportation distances. In daily operations, we are fully advancing the goal of paperless office. By promoting electronic documentation, we have significantly cut carbon emissions generated from unnecessary paper-based files.

By establishing a more transparent emissions baseline, we can formulate targeted and precise emission reduction measures. As the data acquisition system continues to improve, the Group will gradually disclose more relevant Scope 3 categories in the future, consistently enhance the quality of environmental information disclosure, and collaborate with partners to drive the low-carbon transition across the entire value chain.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

During the Reporting Period, energy consumed in our CRO and CDMO operations was mainly sourced from purchased electricity and purchased heat. Diesel consumption primarily arose from power generation and regenerative thermal oxidizer (RTO) operations, while gasoline consumption originated from fleet vehicles. Relevant data are set out below.

Indicator	2024	2025	Unit
Greenhouse gas emissions			
Direct emissions from energy use (Scope 1) ⁴	1,649.49	1,669.78	tCO ₂ e
Indirect emissions from energy use (Scope 2) ⁵	41,819.18	39,401.13	tCO ₂ e
Indirect emissions from energy use (Scope 3) ⁶	674.85	32,581.75⁷	tCO ₂ e
– Category 1: Purchased Goods and Services	First-time disclosure	31,219.30	tCO ₂ e
– Category 2: Capital Goods	First-time disclosure	540.52	tCO ₂ e
– Category 5: Waste Generated in Operations	319.85	734.25	tCO ₂ e
– Category 6: Business Travel	355.00	87.68	tCO ₂ e
Forestry emission reduction	1.59	1.59	tCO ₂ e
Total greenhouse gas emissions (Scope 1 and Scope 2)	42,907.75	39,870.76	tCO ₂ e
Greenhouse gas emission intensity (Scope 1 and Scope 2)	21.59	23.05	tCO ₂ e per RMB million of revenue
Total greenhouse gas emissions (Scope 1, Scope 2 and Scope 3)	43,582.60	72,452.51⁷	tCO ₂ e
Greenhouse gas emission intensity (Scope 1, Scope 2 and Scope 3)	21.94	41.89⁷	tCO ₂ e per RMB million of revenue

⁴ Greenhouse gas (Scope 1) emission data is calculated in accordance with the “Guidelines for Greenhouse Gas Emission Accounting and Reporting for Industrial and Other Enterprises” issued by the National Development and Reform Commission.

⁵ We have adopted the location-based method for the calculation of Scope 2. The calculation method for greenhouse gas (Scope 2) emission data refers to the Announcement on Issuing the 2023 Power Sector Carbon Dioxide Emission Factors by the Ministry of Ecology and Environment of the People’s Republic of China, the Notice on Adjusting Relevant Emission Factor Values in the Municipal Greenhouse Gas Emission Accounting Guidelines issued by the Shanghai Administration of Ecology and Environment, and the default carbon dioxide emission factors for heat in various industrial accounting guidelines promulgated by the National Development and Reform Commission.

⁶ Pursuant to the Greenhouse Gas Corporate Value Chain (Scope 3) Accounting and Reporting Standard (2011), our Scope 3 emissions cover Categories 1, 2, 5 and 6.

⁷ During the Year, Scope 3 emissions newly included emissions from Category 1 (Purchased Goods and Services) and Category 2 (Capital Goods), resulting in an increase in total Scope 3 emissions and intensity compared with the previous year.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Indicator	2024	2025	Unit
Energy consumption			
Petrol consumption	82,762.90	80,299.60	liter
Diesel consumption	312,603.60	21,126.81	liter
Natural gas consumption	2,396.39	94,607.40⁸	cubic metres
Renewable energy ⁹	94.65	100.92	MWh
Total direct energy consumption	3,980.52	1,961.46	MWh
Direct energy consumption intensity	2.00	1.13	MWh per RMB million of revenue
Consumption of purchased electricity	47,260.30	50,918.21	MWh
Consumption of purchased heat	41,563.92	31,272.56	MWh
Total indirect energy consumption	88,824.22	82,190.77	MWh
Indirect energy consumption intensity	44.71	47.53	MWh per RMB million of revenue
Total energy consumption	92,804.74	84,152.23	MWh
Energy consumption intensity	46.71	47.53	MWh per RMB million of revenue

⁸ During the Reporting Period, the Group increased natural gas consumption as it replaced diesel with cleaner-burning natural gas.

⁹ During the Reporting Period, the Group generated and consumed renewable electricity through the installation of solar photovoltaic panels.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

4.3. Waste Management

4.3.1 Waste Gas Management

The Group strictly complies with the Air Pollution Prevention and Control Law of the People's Republic of China, Measures for the Administration of Import and Export of Ozone-Depleting Substances and other regulations, and exercises stringent control over production waste gas. Through continuous monitoring of emission data, the Group ensures key indicators including VOCs fully comply with the Integrated Emission Standard of Air Pollutants, safeguarding clean air through compliant operations.

CDMO Waste Gas Management

For exhaust emissions generated from CDMO operations, the Group maintains sophisticated controls through a suite of management systems, including the Exhaust Management Procedure, Exhaust Treatment Operating Protocol, and Exhaust Absorption Control Policy, with a dedicated focus on minimizing pollutant discharge. The Group has deployed state-of-the-art three-chamber regenerative thermal oxidizer (RTO) systems integrated with resin adsorption technologies to treat halogenated exhaust streams, securing efficient and stable process performance. This integrated system substantially enhances VOC abatement efficiency while delivering optimal thermal energy recovery. Furthermore, engineering optimizations were implemented for expansion joints in the main exhaust pipeline, markedly improving system integrity and mitigating fugitive emissions. Through technological innovation and rigorous monitoring, the Group ensures full compliance with emission limits, upholding its commitment to green pharmaceutical practices.

CRO Waste Gas Management

The Group has established a rigorous exhaust management and monitoring system. A VOC online monitoring system has been installed to enable real-time monitoring of exhaust emissions and early warning of non-compliance, ensuring prompt control of environmental risks.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

For laboratory environments, exhaust from biological laboratories is collectively captured via fume hoods and discharged following deep purification by activated carbon treatment systems. Exhaust from animal facilities is collected through dedicated ventilation systems and treated using identical activated carbon units, ensuring full compliance with environmental standards. Meanwhile, professional maintenance is conducted regularly on biological safety cabinets to guarantee safe and reliable operation. Regarding material management, the Group imposes stringent storage requirements for VOCs-containing materials to minimize fugitive emissions at source. Through such comprehensive exhaust control measures, the Group has achieved effective treatment of laboratory exhaust, making active contributions to environmental protection and sustainable development. During the Year, all monitored exhaust emissions from the Group fully complied with applicable discharge standards.



New High-efficiency Intelligent RTO System

Indicator	2024	2025	Unit
Industrial waste gas emissions			
VOCs	8.19	9.90	tons
Sulfur oxides (SO _x)	0.92	0.80	tons
Nitrogen oxides (NO _x)	7.10	18.50	tons
Vehicle air pollutant emissions¹⁰			
Carbon monoxide (CO)	889.82	687.80	kg
Hydrocarbons (HC)	56.97	54.25	kg
Nitrogen oxides (NO _x)	1,478.38	960.35	kg
Inhalable particulate matter (PM ₁₀)	47.77	29.14	kg
Fine particulate matter (PM _{2.5})	43.17	26.45	kg
Sulfur oxides (SO _x)	1.91	1.40	kg

¹⁰ The vehicle air pollutant emissions were calculated with reference to the Technical Guide for Compilation of Emission Inventory for Air Pollutants from Road Motor Vehicles (Trial) issued by the Ministry of Ecology and Environment of the People's Republic of China.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

4.3.2 Wastewater Management

Viva Biotech maintains a steadfast commitment to aquatic environmental stewardship, with robust protocols governing pharmaceutical wastewater management. Manufacturing effluents are subject to stringent controls in compliance with the Wastewater Management Procedure, Wastewater Treatment Operating Protocol and Wastewater Treatment Facilities Management System. All effluents undergo centralized collection and specialized treatment to achieve full conformity with national discharge standards, minimizing ecological impacts on adjacent water bodies. The Group upholds a transparent and rigorous monitoring framework to mitigate discharge risks to the most stringent criteria, minimizing the hydrological footprint of operations and upholding its environmental accountability as a responsible corporate entity.

CRO Wastewater Management

For its CRO operations, the park is equipped with sophisticated wastewater treatment facilities. Wastewater is subject to integrated collection and treated via a process combining membrane bioreactor, activated carbon adsorption and disinfection, before being transferred to qualified professional institutions for final disposal to ensure proper treatment. Enclosed funnels are adopted during collection to effectively prevent liquid leakage and further enhance operational safety. Sanitary wastewater is treated in septic tanks before being discharged into the municipal sewer system. In addition, the wastewater discharge point is installed with a real-time COD monitoring system, which triggers instant alerts to management when parameters exceed prescribed limits. Through such rigorous control and monitoring measures, the Group ensures full compliance of wastewater discharge and safeguards environmental integrity.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

CDMO Wastewater Management

For CDMO operations, the Group implements a refined wastewater classification strategy. Differentiated collection, transportation and treatment protocols are adopted for high-strength wastewater from production workshops, low-strength wastewater from floor washing, and domestic sewage. By deploying advanced collection tanks and pumping systems within workshops, the Group achieves centralized and efficient wastewater management, ensuring all wastewater is conveyed to treatment facilities via dedicated pipelines. This approach not only enhances the safety of wastewater collection but also ensures stability in subsequent treatment processes, fulfilling the Group’s operational commitment to environmental protection.

CDMO Wastewater Treatment Process

Separation of rainwater and wastewater	By separating rainwater and wastewater to avoid the dilution of wastewater concentration by rainwater, we ensure stability of the biochemical system at wastewater treatment plant, and significantly reduce the risk of polluted natural water due to overflows during rainy seasons.
Separation of clean water and wastewater	By separating clean water and wastewater, we realize direct reuse of clean water for production or greening, and reduce the wastewater treatment volume.
Separation of wastewater	By separating high-pollution wastewater and low-pollution wastewater, we can treat them respectively based on the concentration of pollutants (such as high COD wastewater and general wastewater), by adopting advanced oxidation or biological treatment processes to improve treatment efficiency and reduce chemical consumption.

Indicator	2024	2025	Unit
Wastewater discharge			
Industrial wastewater	161,560.66	174,499.49	tons
– COD	5.21	14.48	tons
– Ammonia nitrogen	0.13	0.28	tons
Domestic sewage	34,275.80	37,982.69	tons

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

4.3.3 Hazardous Waste Management

The Group adheres rigorously to the Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste, National Hazardous Waste List and other statutory requirements. Guided by the management principle of unified collection, categorized treatment, centralized incineration, and risk mitigation, the Group systematically advances the strategic objectives of waste minimization, resource recovery and harmless disposal for hazardous waste. To sustain full regulatory compliance, it has formulated and enforced the Hazardous Waste Management System and Solid Waste Management Procedure, establishing end-to-end closed-loop oversight across the entire lifecycle. Concurrently, the Standard Operating Procedure for Waste Liquid Incineration Systems and detailed process flow diagrams are implemented to ensure full adherence to environmental requirements throughout incineration operations.

The Group demonstrates unwavering accountability in facility maintenance and regulatory compliance. Our hazardous waste storage facilities are constructed in strict accordance with the Control Standard for Hazardous Waste Storage, featuring epoxy flooring and comprehensive four-defense systems (anti-seepage, windproof, rainproof and sunproof), together with clearly visible warning signage. Furthermore, the Group rigorously implements the hazardous waste transfer manifest system and discharge permit monitoring requirements, ensuring full transparency and compliance across all management procedures.

CRO Hazardous Waste Management

For CRO operations, laboratory waste liquids and experimental residues represent the core focus of hazardous waste management. The Group maintains stringent waste categorization protocols and strictly prohibits the commingling of uncontaminated general waste with hazardous waste streams, thereby eliminating avoidable environmental risks and resource inefficiency at source. All reagent containers and laboratory waste are classified as "laboratory-contaminated solid waste", and collected together with other hazardous waste in dedicated hazardous waste warehouses. Prior to storage, authorized personnel conduct mandatory inspection and weighing of waste materials to ensure full consistency between their physical attributes and predefined receiving records. Standardized statutory labels are duly affixed to all packaging vessels in compliance with national requirements.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

To ensure professional and compliant disposal, we engage licensed third-party specialists for collection and treatment. Weekly scheduled removal minimizes on-site storage duration of hazardous waste, safeguarding environmental safety. The Group imposes strict personnel governance over inspection, warehousing, storage, collection and transportation, with clearly defined responsibilities across departments and key roles to establish a robust accountability framework and eliminate potential management lapses.

In 2025, we implemented the following specific measures to further advance the reduction of hazardous waste:

- **Recycling of Raw Material Packaging Drums:** Previously, raw material packaging drums were all disposed of as “laboratory-contaminated solid waste”. Following screening and assessment, we now reuse these drums for waste liquid storage, effectively reducing the generation of laboratory-contaminated solid waste.
- **Optimizing Supplier Packaging Specifications:** For bulk raw materials previously repackaged by the Group, we required suppliers to provide small-package formats directly, eliminating additional laboratory-contaminated solid waste generated from bulk unpacking.
- **Solvent Recycling:** Surplus purchased chemicals/solvents are stored in designated storage rooms for repeated use where necessary.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

CDMO Hazardous Waste Management

In the CDMO sector, we have pioneered the implementation of an intelligent hazardous waste monitoring and control system, which comprehensively elevates the safety and efficiency of waste disposal. The Group has established the Safety Operation Specifications for Waste Liquid Incineration Systems, underpinning the reliable and high-performance operation of waste liquid and solvent incineration through standardized governance. Various process waste liquids and spent solvents are subjected to high-temperature thermal treatment. Throughout the disposal process, stringent controls are imposed on the feed rates of acidic contaminants, heavy metals and alkali metals, which effectively mitigates equipment corrosion and prolongs service life. Following an integrated purification sequence, waste liquids and spent solvents are fully converted into flue gas. The system is equipped with state-of-the-art flue gas treatment facilities supported by real-time online flue gas monitoring, ensuring all emission parameters fully comply with regulatory standards prior to stack discharge. This integrated framework enables high-efficiency treatment of solvent-bearing waste, substantially reduces the overall volume of solvent waste, and delivers robust support for sustainable manufacturing.



Waste Liquid and Wastewater Incineration System with Supporting Flue Gas Treatment Facilities



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

During the Reporting Period, the primary hazardous wastes generated from the CRO segment consisted of waste fuels and chemicals from chemical laboratories. Hazardous wastes arising from the CDMO segment mainly included waste residues, waste activated carbon, waste solvents, high-boiling residues, waste salts, waste samples, waste packaging materials, wastewater treatment sludge, waste mineral oil, etc. Relevant data are presented below:

Indicator	2024	2025	Unit
Hazardous waste			
Waste fuel and chemicals ¹¹	2,851.13	3,627.61	tons
Organic waste liquid	393.49	452.21	tons
Laboratory solid waste and glass	92.75	142.74	tons
High-boiling residue	1,164.51	1,166.84	tons
Waste salt	1,840.50	1,441.45	tons
Sludge	288.78	551.51	tons
Other hazardous waste ¹²	1,167.18	1,148.43	tons
Total amount of hazardous waste	7,798.34	8,530.78	tons
Hazardous waste intensity	3.93	4.93	tons per RMB million of revenue

¹¹ Waste fuel and chemicals include waste acid, waste alkali, waste organic solvent, etc.

¹² Other hazardous waste includes waste residue, waste activated carbon, waste packaging barrels, waste packaging bags, waste mineral oil, waste samples, fly ash, slag, etc.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

4.3.4 Non-hazardous Waste Management

Committed to rigorous environmental governance, the Group has established a standardized management system in accordance with the Solid Waste Management Procedures, exercising full-process control over waste collection, classification and disposal. During the Reporting Period, responding to updates in national regulations, the Group completed the revision of the Solid Waste Management Program, comprehensively optimizing identification systems including the hazardous waste labels, storage zone signs and storage facility signs. Concurrently, the formats of transfer manifests for hazardous waste and general industrial solid waste were updated, with enhanced management ledgers improving traceability efficiency.

For general industrial solid waste, we maintain dedicated storage facilities equipped with anti-seepage, rain-proof and dust-control measures to ensure full compliance with the Standard for Pollution Control of Storage and Landfill of General Industrial Solid Waste. All wastes are strictly classified into four categories: recyclable, non-recyclable, general solid waste and hazardous waste. We have strengthened recycling of paperboard, plastics, metals and other materials, and entrust qualified professional entities for disposal, thereby maximizing resource utilization and fulfilling our environmental protection responsibilities.

In 2025, we implemented the following specific measures to further reduce the generation of non-hazardous waste

- Reused waste packaging derived from general industrial solid waste for packaging solid hazardous waste;
- Optimized expansion joints on the main exhaust gas pipeline, thereby lowering the risk of exhaust gas leakage;
- Expanded solvent tank farm and implemented piped material transfer, thereby minimizing exhaust emissions during material handling and transfer;
- Developed reagent procurement plans at the source, procuring quantities strictly based on project-specific requirements;
- Upgraded solvent recovery facilities and enhanced solvent recovery rates, thereby minimizing solvent consumption and loss;
- Strengthened promotion and awareness initiatives for the Zero-Waste Factory development.



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

Category	Solid waste	Storage and disposal methods
Recyclable general solid waste	Waste paper: office waste paper, used books, old newspapers, cartons, etc.	Small quantities may be placed in the “recyclable solid waste” bins. Large volumes of recyclable general solid waste shall be delivered directly to the Company’s temporary waste storage area.
	Plastics: packaging films, waste rubber, waste plastic drums, etc.	
	Metals: iron, copper, scrapped metal equipment and accessories, discarded tools, etc.	Valuable waste such as waste cartons and scrapped metals shall be disposed of by qualified waste collectors, while remaining non-valuable harmless waste shall be disposed of by sanitation companies.
	Restaurant leftovers, etc.	Collectively deposited into food waste bins before being transferred to the park for kitchen waste treatment.
Non-recyclable general solid waste	Other domestic waste	Placed in “non-recyclable solid waste” bins and disposed of by qualified disposal entities.

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

During the Reporting Period, the non-hazardous waste generated by Viva Biotech mainly included general solid waste and domestic waste generated from daily office operations and production. Relevant figures are set out as follows:

Indicator	2024	2025	Unit
Non-hazardous waste			
Waste paper	26.42	20.87	tons
Waste glass	0	0.39	tons
Waste plastic	13.78	13.60	tons
Scrap metal	371.15	354.97	tons
Fly-waste and waste cotton	117.33	72.07	tons
Waste packaging	41.68	29.53	tons
Kitchen waste	69.27	84.11	tons
Other waste	193.71	172.50	tons
Total amount of non-hazardous waste	833.55	748.04	tons
Non-hazardous waste intensity	0.42	0.43	tons per RMB million of revenue



4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

4.4. Resource Management

4.4.1 Water Resource Management

Committed to valuing water resources, the Group adopts water conservation measures in compliance with the Energy and Resource Management Procedure, with a view to optimizing resource allocation and managing water consumption. Freshwater is sourced from the municipal water supply network, ensuring stable supply with no disruptions experienced.

We have established a comprehensive emergency operation procedure for water outages, with detailed response protocols developed for diverse scenarios including municipal water supply interruption, circulating water failure, boiler feed water cutoff, and cooling tower water shutdown. This ensures the production system operates safely and steadily under all emergency conditions.

To further unlock water conservation potential, the Group requires all departments and workshops to enhance recovery and reuse of cooling water and steam condensate to the extent practicable, substantially elevating the efficiency of integrated water resource utilization. For domestic facilities, water-efficient valves have been installed in flush toilets to effectively eliminate instances of “continuous water flow”. Automatic sensing fixtures have been fully deployed to further reduce water consumption through technological means. Propelled by refined management and infrastructure upgrades, the Group is committed to building a water-efficient enterprise and achieving sustainable resource utilization.

Water Conservation Sign

During the Reporting Period, our water consumption is as follows:

Indicator	2024	2025	Unit
Use of water resources			
Water consumption	209,846.00	224,416.86	tons
Water consumption intensity	105.63	129.76	tons per RMB million of revenue

4. ENVIRONMENTAL BENEFITS AND ECOLOGICAL PROTECTION

4.4.2 Packaging Materials Management

The Group regards packaging material management as a critical component in advancing the circular economy, and reduces resource consumption through diversified management measures. At present, packaging materials employed by the Group mainly consist of cartons, fiber drums and various types of packaging bags.

Adhering to the principles of “reduction, reuse and recycling”, the Group continuously optimizes packaging design to reduce material consumption, actively introduces eco-friendly packaging materials, and explores the application potential of biodegradable technologies. Through internal education and awareness initiatives as well as performance incentive mechanisms, the Group elevates all employees’ focus on packaging recycling. In addition, the Group extends corporate responsibility to customers, promotes joint recovery of packaging materials, and mobilizes all stakeholders to contribute to environmental sustainability.

During the Reporting Period, our consumption of packaging materials is as follows:

Indicator	2024	2025	Unit
Consumption of packaging materials			
Total consumption of packaging materials	99.46	195.54	tons
Packaging material consumption intensity	0.05	0.11	tons per RMB million of revenue



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

Viva Biotech firmly believes that talent constitutes the fundamental impetus for corporate development. Guided by the philosophy of “people-centricity”, we foster a diverse and inclusive workplace where diverse insights and individual potential converge and prosper. We place paramount importance on employees’ physical and mental well-being and occupational safety, while endeavoring to establish a robust development platform to realize their professional aspirations. While enhancing the Group’s competitiveness, we remain committed to giving back to society through human-centric care, pursuing the synchronized advancement of economic and social values. On the basis of shared growth, the Group and its employees achieve long-term, sustainable mutual benefits and win-win results.

Corresponding UNSDGs:



5.1. Employment Compliance and Employee Benefits

5.1.1 Employment Management

The Group regards talent as its most valuable asset and is committed to integrating equity, diversity and inclusion into every aspect of human resource management. We ensure that decisions relating to recruitment, promotion, remuneration and training are based on competence and fairness, in strict compliance with the Labour Law of the People’s Republic of China, the Labour Contract Law of the People’s Republic of China and other applicable laws and regulations. Through internal policies including the Wage Management Procedure and Anti-Discrimination Management Procedure, we have established a standardized employment system. We firmly believe that diverse teams drive innovation. Any form of discrimination based on gender, disability, marital status, sexual orientation, age, political opinion, religious belief, race or nationality is strictly prohibited. We are dedicated to fostering an equitable workplace where every employee can fully realize their potential.

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

The Group adopts stringent controls to safeguard labor rights and upholds a zero-tolerance policy on child labor and forced labor. Rigorous identity verification and supplier assessment mechanisms are implemented to ensure ethical compliance across all operations. With regard to the remuneration system, we have clearly defined calculation methodologies and benefit standards to ensure transparency in compensation distribution. Working hours are arranged flexibly in accordance with applicable laws, thereby protecting employees' rights to rest and other lawful entitlements.


With regard to remuneration and working hour management, the Group has established a comprehensive wage management procedure to enhance transparency in compensation, subsidies, benefits and their disbursement processes. Through the Working Hour Management Procedure, we regulate overtime, attendance and various leave arrangements. For specialized job types, we adopt the comprehensive working hour system or non-fixed working hour system in accordance with laws, fully protecting employees' legitimate rights and interests. Furthermore, the Company fully upgraded its human resource service system during the Year, integrating attendance, onboarding and offboarding procedures, as well as employment certification services onto an integrated platform. Such system upgrade has not only achieved process automation and real-time information updates, but also enhanced management efficiency via data visualization, providing robust support for the Company's decision-making.

The Group's employee structure underscores its unwavering commitment to diversity and professionalization. We endeavor to foster an inclusive work environment with a balanced gender distribution of 55% male and 45% female. The workforce demonstrates a distinct youth-oriented trend, with employees under 30 accounting for 52%, injecting sustained innovation vitality into corporate development. In terms of talent deployment, the Group places paramount emphasis on R&D and innovation, with R&D personnel representing 60% of total employees, forming the core driving force for growth. In addition, our employees are widely located in Shanghai, Jiaxing, Chengdu, Ningbo, Taizhou, Suzhou and overseas regions. Such extensive geographic distribution not only strengthens the Group's global business coverage but also provides employees with broader career development prospects and platforms for self-actualization.




5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY


Total number of employees by gender




Total number of employees by geographical region



Total number of employees by nature



Total number of employees by age groups



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

Indicator	2024	2025
Total number of employees¹³	2,063	2,169
Number of employees by gender		
Male	1,130	1,198
Female	933	971
Number of employees by age		
Aged under 30	1,148	1,137
Aged 31-40	541	606
Aged 41-50	209	252
Aged over 50	165	174
Number of employees by region		
Shanghai	1,028	1,072
Jiaxing	145	130
Chengdu	92	81
Ningbo	93	84
Taizhou	547	639
Suzhou	150	149
Hong Kong	0	0
Overseas ¹⁴	8	14
Total employee turnover rate¹⁵	14%	14%
Employee turnover rate by gender		
Male	15%	16%
Female	14%	12%
Employee turnover rate by age		
Aged under 30	16%	18%
Aged 31-40	14%	10%
Aged 41-50	13%	9%
Aged over 50	7%	7%
Employee turnover rate by region		
Shanghai	13%	11%
Jiaxing	4%	12%
Chengdu	13%	23%
Ningbo	11%	17%
Taizhou	20%	17%
Suzhou	11%	19%
Hong Kong	26%	0%
Overseas	0%	7%

¹³ During the Year, the Group had 2,168 full-time employees and 1 part-time employee.

¹⁴ Our overseas regions include North America, Australia and the United Kingdom.

¹⁵ Employee turnover rate refers to the percentage obtained by dividing the number of employees leaving in a given category during the Reporting Period by the end-of-period headcount of such category during the Reporting Period.



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.1.2 Employee Benefits and Care

The Group regards employee benefits as a core component of its talent strategy. By establishing a highly competitive and comprehensive benefits system, we unlock employee potential and strengthen organizational cohesion. Our benefit portfolio encompasses not only basic statutory protections but also living allowances and long-term health management programs, aiming to optimize the talent retention environment in all respects.

With respect to employee benefits, we strictly implement national statutory requirements and provide fundamental protections including social insurance and housing provident fund, commercial insurance and paid annual leave. For employees with childcare responsibilities, we offer maternity leave, prenatal check-up leave and breastfeeding leave for female employees, as well as paternity leave and parental leave for male employees, fully supporting employees in fulfilling their family obligations. In addition, we provide flexible benefits such as meal allowances, transportation allowances, employee care provisions, festival benefits and regular occupational health examinations. Specifically, employees are entitled to a 2-hour “casual welfare leave” once per month to flexibly address various ad-hoc or unexpected matters. Through these thoughtful and targeted care initiatives, we strive to enhance employee well-being and achieve a harmonious work-life balance.

In respect of health and living security, the Group regularly arranges full-staff physical examinations and distributes festival and birthday benefits to convey corporate care. To address employees’ commuting and accommodation needs, we provide shuttle bus services, and offer dormitories for fresh graduates, interns and employees with short-term accommodation needs. A dedicated expatriate allowance scheme is established for employees on cross-regional assignments, ensuring care is extended to every employee.

For team cohesion development, the Group appropriates dedicated funds to support a diverse array of departmental activities, including Spring Festival annual meetings, team-building events and outdoor development programs, thereby strengthening collaboration and camaraderie across the workforce. To enhance the agility of employee benefits, we have implemented the CareLink welfare platform, which consolidates meal allowances, festival gift packages and merchant preferential offers to tailor benefits to individual employee needs. We firmly maintain that a sophisticated benefits framework effectively reinforces organizational solidarity. Moving forward, the Group will persist in optimizing the system to foster a premier workplace environment.

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

Selected welfare and team-building activities during the Year:



Spring Festival Gala



Departmental Team-Building Events



Outdoor Development Programs



“Unite & Inspire” Team-Building Events



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.1.3 Employee Communication

To ensure efficient and transparent operations, the Group continuously refines its employee communication system and establishes a comprehensive feedback mechanism through digital tools and institutionalized channels.

We have established a bridge between employees and management through a professional HRBP team, which not only addresses practical concerns raised by employees but also translates their feedback into drivers for management optimization. In terms of digital transformation, upgraded management platforms and working groups have eliminated geographical constraints on communication. Business inquiries and administrative approvals are addressed in a timely manner, significantly enhancing work engagement and efficiency.

To enhance communication efficiency, the Group has established dedicated work teams to facilitate two-way interactions among employees, enabling real-time information sharing and prompt responses. Concurrently, the upgraded human resource management system provides employees with an integrated and streamlined communication channel. Through this platform, employees may efficiently conduct business communications, submit applications for approvals, and make relevant inquiries, which has significantly elevated operational efficiency and communication effectiveness.

For new recruits, the Group has launched the Sail-Start Program, featuring diversified team activities and structured onboarding guidance to accelerate integration and foster mutual understanding and collaboration among employees. The introduction of the General Manager's Mailbox underscores the Group's emphasis on frontline feedback. Under the standardized "investigation-handling-response" process, the Group commits to issuing a written reply in the Employee Complaints and Feedback Record within five working days upon completion of review and disposition, ensuring all employee input is duly considered and addressed.

The Group also encourages informal interactions between management and employees. Through team-building events, sports competitions, recognition ceremonies for high-performing employees and other activities, we further strengthen interpersonal connections. In a collaborative and inclusive atmosphere, management and employees jointly advance corporate culture development and foster a strong foundation of mutual trust, enabling Viva Biotech to serve as a supportive community for the shared growth of all employees.

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.2. Diversity, Equality and Inclusiveness

Viva Biotech has long upheld diversity, equity and inclusion as the cornerstones of its workplace culture. We are committed to delivering holistic support to employees at every stage of their professional careers while fostering a fair and impartial competitive environment. Targeted efforts are deployed across organizational structure, staff training, female employee benefits and anti-discrimination practices to cultivate an open and inclusive workplace atmosphere.

In talent recruitment, the Group actively embraces multi-dimensional diversity across gender, age, cultural and educational backgrounds. Pursuant to the Anti-Discrimination Management Procedures, the Group maintains a strict zero-tolerance policy against all forms of discrimination and is committed to securing equal employment opportunities for persons with disabilities. During the Year, the Group appointed persons with disabilities to fundamental administrative positions, translating its dedication to respect and care for vulnerable groups into tangible actions. Meanwhile, the Group places paramount emphasis on the rights and interests of female employees. With user-centric facilities including lactation rooms in place, we facilitate the seamless return of female employees to the workplace.

By fostering an inclusive culture, Viva Biotech has successfully transformed diverse backgrounds into competitive advantages. We pledge to continuously refine our diverse talent ecosystem, remove barriers to career development, and enable every Viva member to achieve their full potential while jointly shaping the Group's long-term development blueprint.

Women's Day Welfare Activities

On the warm International Women's Day, the Group expressed sincere gratitude to all female employees for their outstanding contributions at work. Special arrangements were made for the delivery of fresh fruit and the provision of cash benefits, embodying the Group's care in every detail. This gesture not only recognizes their diligent efforts but also demonstrates the Group's profound emphasis on and enduring commitment to the well-being of female employees.





5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.3. Occupational Health and Safety

Viva Biotech consistently places the physical and mental well-being of its employees at the core of its operations. The Group fully adheres to the Work Safety Law of the People’s Republic of China, the Labor Law of the People’s Republic of China, the Law on Prevention and Control of Occupational Diseases and other applicable laws and regulations, while steadily enhancing its occupational health and safety governance system. It has systematically forged a comprehensive safety management framework featuring risk evaluation, operational control and emergency response mechanisms.

Each park houses a dedicated EHS department with overall responsibility for workplace safety, routine safety inspections, and oversight of regular training and drills. The Group has formulated the EHS Change Management Procedures, specifying refined risk grading criteria and implementation monitoring processes. Concurrently, a three-year document review cycle has been established to dynamically optimize management system documents in line with updated regulatory requirements, effectively strengthening full-lifecycle safety governance over all change matters.

During the Year, the CDMO segment has attained the ISO 45001 Occupational Health and Safety Management System Certification and the Grade II Standardization Certificate for Work Safety. These achievements represent authoritative recognition of the Group’s safety management capabilities and mark a significant advancement in its commitment to upholding elevated standards for employee health and safety.

The Group has established a series of objectives pertaining to occupational health and safety, with a view to fostering an even safer and healthier workplace for all employees.

CRO safety goals:

0 fatality, serious injury, fire, explosion, poisoning, environmental pollution and safety accident	0 hazardous chemical (including hazardous waste) leakage accident or culpable traffic accident
100% timely report of information on identification of hidden dangers	99% of the hidden dangers are timely rectified
95% of safety facilities in good condition	100% timely report of safety accidents
100% participation rate and passing rate of safety training	100% timely occupational health examinations

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

CDMO safety goals:

0 fatality, serious injury, fire, explosion, poisoning, environmental pollution and safety accident	0 hazardous chemical (including hazardous waste) leakage accident or culpable traffic accident
100% timely report of information on identification of hidden dangers	100% of the hidden dangers are timely rectified
98% of safety facilities in good condition	100% timely report of safety accidents
100% participation rate and passing rate of safety training	100% timely occupational health examinations

During the Reporting Period, the Group was not aware of any material violations of laws and regulations relating to occupational health and safety. Meanwhile, no work-related fatalities have occurred in the latest three years, including the Reporting Period.



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.3.1 Safety Inspection

The Group has established a sophisticated hierarchical EHS management and control system. Through a dual-track model integrating the “Intelligent Inspection System” and “Manual Trace Inspection”, we have realized dynamic monitoring of production and laboratory premises. In response to the unique risk attributes of laboratories, we have formulated dedicated safety manuals and a rigorous violation points-based management system. The EHS team conducts on-site inspections jointly with laboratory safety officers on a weekly basis, and performs quarterly comprehensive assessments of safety conditions in laboratories and workshops in accordance with the points deduction mechanism. The assessment covers waste disposal, employee operational compliance, facility standardization, storage management and other dimensions. In addition, the EHS team also conducts regular equipment inspections. Any faulty equipment identified is immediately referred to the engineering team or outsourced maintenance vendors for servicing, ensuring equipment remains in sound condition at all times. During the Year, laboratories achieved outstanding performance in environmental hygiene and safety management, with no serious violations detected. We will continue to strengthen inspection efforts to ensure stable laboratory operations and provide a solid and reliable guarantee for scientific research and innovation.

5.3.2 Occupational Disease Prevention and Management

The Group is committed to establishing a comprehensive and effective occupational disease prevention and control system. We have formulated and implemented a series of rigorous management systems, including the Occupational Disease Hazard Monitoring and Evaluation Management System, Occupational Disease Hazard Warning and Notification System, Occupational Disease Hazard Prevention and Control Publicity, Education and Training System, and Occupational Disease Hazard Prevention and Control Responsibility System, providing clear institutional guidance and compliance safeguards for occupational health initiatives.

The Group’s Leading Group for Occupational Health Administration collaborates closely with the EHS Department to assign occupational hazard prevention and control tasks to specific positions and hold individuals accountable. We recognize the value of external professional assessments and regularly entrust third-party institutions to conduct hazard factor monitoring. During the Year, occupational disease hazard factor monitoring was implemented at the Shanghai Zhoupu, Chengdu and Suzhou Parks. All monitoring data for respective positions met the required standards, demonstrating the Group’s outstanding effectiveness in risk management and control.

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

Occupational disease prevention

We have not only installed standardized warning signs throughout the workplace but also institutionalized the distribution and compliance inspection of personal protective equipment. Meanwhile, the Group actively promotes the development of an occupational health culture, enhancing employees' self-protection capabilities through diverse education and training initiatives. Going forward, we will continue to deepen occupational disease prevention and control, and drive the Group's high-quality development through high-standard safety management.

Occupational health examinations

The Group has always placed employees' health protection as a top priority and established a full-cycle occupational health surveillance system. We strictly implement pre-job, in-service and post-employment occupational health examinations to ensure that every employee receives a comprehensive occupational health check-up once a year. For employees returning to work after maternity leave, the Group adopts human-centered protection measures by first arranging their transfer from high-hazard positions, and reassigning them to their original posts only after their physical condition is confirmed to be suitable. To ensure the scientificity and effectiveness of examinations, check-up items are tailored according to employees' length of service involving chemical exposure and primary hazard factors. We have also developed biological and chemical examination registers for different positions to precisely identify occupational disease hazards. In the event that any employee is suspected of having an occupational disease during examination, the Group will immediately arrange a re-examination; for confirmed cases, proactive medical treatment will be provided. During the Year, no suspected occupational disease cases were identified within the Group.

Furthermore, we require employees to regularly sign the Occupational Hazard Notification Statement, which truthfully informs them of potential hazards, consequences, protective measures and relevant entitlements arising in the course of work, effectively safeguarding employees' right to information and right to health. Through these initiatives, we have not only enhanced the awareness of all employees regarding occupational disease prevention and control, but also established a safe and healthy workplace environment.



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.3.3 Equipment Safety and Hygiene Management

To ensure the inherent safety of production facilities and operational processes, the Group implements rigorous process safety management and process hazard analysis. Under core guidelines including the Production Facility Safety Management System and Carcinogen Management Procedure, we incorporate occupational health risks into full life-cycle management to guarantee the precise implementation of all protective measures.

In terms of facilities, the Group is committed to creating a safe working environment in compliance with national standards. Laboratory noise reduction, ventilation, toxic protection and ionizing radiation protection equipment are all installed to high standards in accordance with the Hygienic Standards for the Design of Industrial Enterprises, ensuring the superior performance of occupational health protection facilities. For new construction, reconstruction and expansion projects, we strictly implement the occupational health “Three Simultaneities” supervision mechanism (simultaneous planning, simultaneous construction, and simultaneous operation). Qualified third-party institutions are entrusted to conduct occupational disease hazard factor monitoring. During the project feasibility demonstration phase, a pre-evaluation of occupational disease hazards is conducted and relevant reports are compiled to ensure that safety planning precedes construction.

In terms of hygiene control, we dynamically identify and assess the biosafety levels of biological laboratories and production exposure sources. For high-risk processes, the Group adopts advanced engineering control measures to strictly limit exposure levels within occupational exposure limits. Meanwhile, we require employees entering relevant areas to wear full protective equipment and complete specialized training, coupled with regular disinfection and sterilization, to comprehensively safeguard employee health and the safety of the research environment.

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.3.4 Occupational Health and Safety Training

To effectively manage operational risks, Viva Biotech is committed to enhancing employees' occupational health protection capabilities through systematic training. We implement the Viva Biotech Safety Education and Training Management System, and provide tailored training programs based on the needs of different positions, particularly high-risk roles involving frequent contact with biological agents. The content focuses on the response to potential laboratory hazards and proper use of protective equipment. Timely evaluation and assessment are conducted to ensure knowledge is translated into practical skills.

We include safety training as a compulsory course for new and transferred employees, ensuring they acquire comprehensive protection skills before engaging in biological experiments. The Group also reinforces the emergency response and safe operation capabilities of all staff through regular retraining programs, and strictly implements a record-keeping system. Scientific management underpins the Group's sustainable safe operations.

We are committed to providing employees with comprehensive occupational health and safety protection to ensure a safe and stable working environment. As of the end of the Reporting Period, our health and safety training had reached a total of 6,405 participants. Among them, the CRO business carefully designed and conducted safety-themed training for a total of 2,440 participants and fire drills for 1,372 participants. The CDMO business held at least 8 health and safety special training sessions covering case analysis, safety knowledge promotion and emergency response procedures. Through systematic education and practical drills, we have further enhanced employees' safety awareness and emergency response capabilities, building a solid safety foundation for the steady operation of the Company.



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

Fire Month Activities

During the Fire Month this Year, Langhua Pharmaceutical carried out a series of competitive activities, including tug-of-war competitions, fire fighting skills contests and other events. We aim to enable employees to proficiently master fire safety knowledge, fire-fighting skills and emergency response procedures through a combination of training, competitions and drills, establish a safety management pattern of “Fire Safety for All, Life First and Foremost”, and build a solid line of defense for safe production.



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.3.5 Emergency Response to Accidents

Viva Biotech has established a comprehensive emergency response system. We have formulated safety standard operating procedures (SOPs) for each major piece of equipment and process, specifying detailed emergency operations and response procedures under abnormal conditions. These procedures cover all major deviation or failure scenarios, enabling rapid activation and effective response in the event of sudden safety and environmental incidents.

The emergency response plan not only covers various internal emergencies but also ensures effective alignment with external emergency systems, enabling timely notification and coordinated response in the event of major or serious environmental incidents occurring at neighboring enterprises. The Group has established a dedicated emergency rescue organization responsible for the command and implementation of emergency responses. In addition, we regularly conduct various forms of emergency drills. Through practical simulations, we continuously enhance employees' emergency response capabilities and safety awareness, comprehensively safeguarding the Group's production safety and environmental stability.

The work-related injury cases recorded during the Year were sudden accidents that did not result in serious consequences. We have properly handled and arranged such cases in accordance with the relevant provisions of the Group's Work-related Injury Insurance Regulations. Through continuous improvement of systems and procedures and strengthened safety training, we fulfill our commitment to employees' health and safety.

Indicator	2024	2025	Unit
Lost working days due to work injury	121.5	781 ¹⁶	day
Number of work-related fatalities	0	0	person

¹⁶ During the Reporting Period, a traffic accident occurred outside the factory premises, and the work-related injuries resulting from this incident accounted for the majority of the Group's lost workdays.



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.4. Human Capital Development

5.4.1 Talent Attraction and Recruitment


Talent reserve lies at the core of the Group’s sustained industry competitiveness. We adopt a dual-track strategy of campus recruitment and social hiring, and design tailored acquisition programs for diverse talent groups, striving to attract and retain outstanding professionals worldwide.

For core R&D departments including computational chemistry, biology and chemistry, we attract top graduates through efficient online campus recruitment platforms, supported by competitive compensation structures and clear career progression paths. The Group closely monitors market trends and offers comprehensive benefits including allowances, special innovation grants, multiple rounds of option incentives and talent apartments, fully supporting scientific and high-skilled talents.

For overseas and returnee high-caliber talents, the Group provides “one-stop” support including assistance with work visas and green card applications, as well as commercial insurance and paid home leave. For returnee experts, we offer customized relocation packages and actively connect with government talent policies to help apply for various special subsidies. By building a high-quality career platform and a livable living environment, we continuously optimize the talent ecosystem and inject impetus into long-term development.

Percentage of high-level talents in our CRO business:

Breakdown of educational backgrounds of our CRO employees in 2025



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

Internship & Site Visit by Students from Taizhou University

During the Year, we invited a total of 120 students and faculty majoring in Pharmaceutical Engineering from Taizhou University to visit and study at our Langhua Pharmaceutical campus. They toured key facilities including production workshops, central control rooms, R&D laboratories and analytical testing centers.

The event strengthened university-industry collaboration, while offering students a direct understanding of job responsibilities and real-world business operations. Such immersive engagement greatly enhanced students' identification with the Group and their enthusiasm to join, laying a solid foundation for our future campus recruitment and talent pipeline development.






5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.4.2 Talent Retention and Promotion

To ensure outstanding talents continue to create long-term value for the Group, we have established a robust career development system that provides clear growth paths and a fair competitive environment. We adopt a dual-track promotion structure featuring “management” and “technical” tracks, allowing employees to pursue development directions tailored to their professional strengths and interests. Promotion reviews are conducted each April and October for high-performing employees or those with exceptional contributions. Adhering to the principles of fairness, impartiality and transparency, we comprehensively evaluate candidates’ integrity, professional competence and development potential.

Illustrative promotion ladders



As for performance management, the Human Resources Department oversees the annual company-wide employee appraisal. Each business unit sets professional indicators based on its functional characteristics to ensure objective and accurate evaluation. Appraisal results serve not only as the basis for talent selection and retention but also directly determine annual salary adjustments, motivating employees to pursue continuous self-improvement. In addition, the Group implements both monetary and non-monetary incentives through performance bonuses and outstanding employee recognition programs. For core employees with three or more years of excellent service, we have launched the “Long-Term Service Bonus Plan”. Under this scheme, eligible employees sign a five-year service agreement, with bonuses distributed proportionally throughout the period. The initiative aims to build long-term partnerships, retain loyal and high-performing talent, and create shared value for the Group.

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.4.3 Talent Motivation

The Group actively fosters a diversified employee incentive system designed to unlock intrinsic motivation and achieve the integration of individual and corporate values. Through long-term service agreements and an annual bonus scheme tied to salary ratios, we have built a highly loyal and efficient professional team. To reflect varying roles and contributions, the Group has established multiple awards including project bonuses, public safety awards and quarterly outstanding employee awards, recognizing exceptional performance in key areas. We also offer benefits such as trips to strengthen employee belonging and fulfillment. For on-site resident staff, we provide various allowances and additional bonuses to demonstrate care and recognition.

To enhance talent retention effectiveness, the Group has specially launched the “Long-Term Service Bonus Plan” for outstanding core employees with three or more years of service, establishing long-term strategic partnerships. Beyond individual monetary rewards, we equally emphasize boosting team morale. Targeted recognition for high-performing departments promotes cross-departmental collaboration and resource integration. This comprehensive, multi-layered incentive system not only strengthens the Group’s market competitiveness but also fosters a positive, unified internal culture, providing sustained innovation and execution capabilities in support of the Group’s long-term strategic objectives.



Outstanding Employee Recognition Ceremony



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

5.4.4 Training and Talent Development

Against relentless shifts in the marketplace, the Group upholds the ethos of “Relentless Learning” as fundamental to its competitive strength. Governing all talent development is our formal Employee Training Management Framework, which underpins a structured annual curriculum designed to advance expertise across technical and professional domains.

We adopt an integrated internal and external training strategy that underscores a deep fusion of theory and practice. Training primarily combines structured instruction with hands-on application, enabling employees to translate theoretical knowledge into practical competence through immersive exercises. We have also established a robust system for monitoring training effectiveness, with reinforced appraisal and incentive mechanisms designed to ensure learning outcomes translate directly into improved organizational performance.

The Group places strong emphasis on internal knowledge transfer and is committed to building a high-caliber internal trainer system. We select outstanding business professionals as instructors and provide specialized training on teaching methodologies to continuously enhance instructional quality. Based on participant feedback and satisfaction ratings, we regularly recognize top-performing trainers, fostering a workplace culture that promotes mutual learning between instructors and learners. These initiatives not only elevate the team’s professional competence but also strengthen cultural cohesion, creating sustainable long-term value for the Group.

We design tailored training programs aligned with the unique functions and practical needs of each department. Such diverse training initiatives have substantially strengthened employees’ professional capabilities, built a high-quality talent pool for sustainable development, and maintained the Group’s leading position amid intense market competition.

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

During the Year, we focused on the following five major training programs:

- **New Employee Training:** To help new hires quickly adapt during their induction period, the Company assigns a dedicated mentor to provide “one-on-one” guidance. Basic training covering professional ethics, safety protocols and corporate values is also provided to facilitate new employees’ integration into the corporate culture and smooth transition into their roles.
- **General Skills Courses:** Covering basic professional competencies, project management, GMP training, safety-related training, HR skills enhancement and business ethics. These courses enable employees to regularly review and reinforce general safety protocols and ethical standards.
- **Professional Knowledge Lectures:** Targeted empowerment is provided based on varying professional levels and job requirements. For project managers, emphasis is placed on enhancing management capabilities to facilitate team goal delivery; for senior management, focus is given to nurturing leadership and strategic vision to improve decision-making competence.
- **English Training:** Aligned with the Group’s international business objectives, internal and external instructors deliver practical training focused on daily business communication and negotiation. Clear learning assessment requirements are established to motivate employees, enhance their ability to engage with global information, and broaden their international outlook.
- **“Face-to-Face with Scientists”:** Open to all employees, this initiative offers direct access to cutting-edge industry technologies and opportunities for dialogue with the Group’s leading scientists. It enables employees to gain in-depth insight into corporate strategy, pursue cross-disciplinary learning, and contribute insights to the Group’s development from diverse perspectives.

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY



New Employee Training



“Face-to-Face with Scientists”



Professional Skills Training



Fire Safety Training

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

Set out below is an overview of our training information during the Reporting Period:

Indicator		2024	2025	Unit
Total number of employees trained		1,266	1,421	person
Percentage of employees trained by gender ¹⁷	Male	59%	61%	/
	Female	41%	39%	/
Percentage of employees trained by employee category	R&D staff	46%	49%	/
	Management staff	4%	4%	/
	Other staff	50%	47%	/
Average training hours by gender ¹⁸	Male	20	36	hour
	Female	8	17	hour
Average training hours by employee category	R&D staff	5	5	hour
	Management staff	8	3	hour
	Other staff	40	86¹⁹	hour

¹⁷ Pursuant to the recommendations on data calculation methods set out in Appendix III – Social Key Performance Indicators Reporting Guidelines of “How to Prepare an Environmental, Social and Governance Report” issued by the Hong Kong Stock Exchange, the percentage of trained employees by gender is calculated as the number of trained employees in the respective category divided by the total number of trained employees.

¹⁸ Pursuant to the recommendations on data calculation methods set out in Appendix III – Social Key Performance Indicators Reporting Guidelines of “How to Prepare an Environmental, Social and Governance Report” issued by the Hong Kong Stock Exchange, the average training hours by gender is calculated as the total training hours of employees in the respective category divided by the total number of employees in that category.

¹⁹ During the Reporting Period, we expanded our training courses and coverage, particularly in relation to CDMO operations, thereby increasing average training hours.



5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY



5.5. Community Responsibility and Contribution

Viva Biotech is committed to creating social value through its operations and fulfilling its corporate citizenship obligations via systematic public welfare initiatives and educational support. We attach importance to community well-being and actively contribute to society through regular material donations and employee volunteer activities. In the education sector, we focus on improving educational accessibility and quality, fostering a more inclusive model of social development.

Educational public welfare activities

During the Reporting Period, the Group achieved significant results in industry-university collaboration. Langhua Pharmaceutical, a subsidiary of the Group, cooperated closely with Taizhou University, Shenyang Pharmaceutical University and other institutions. It has established a high-quality internship base covering 5,600 square meters, providing stable internship opportunities each year. During the Reporting Period, the base received approximately 700 student visits and was successfully selected as a Provincial Industry-Education Integration Demonstration Base. As a partner of Toumen Port Modern Industry College, the Group not only provides practical platforms for current students but also optimizes talent development pathways through in-depth industry-education integration, contributing substantial value to industrial prosperity and social equity.

5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY





5. PEOPLE-ORIENTED AND HARMONIOUS COMMUNITY

Summer Open Day Program

During the Year, the Company successfully held 6 Summer Open Day sessions designed to provide a safe, fulfilling and enjoyable holiday experience for the children of its staff, further fostering a caring workplace environment. The activities were diverse and engaging, including creative workshops, fun games, warm birthday celebrations and a fascinating laboratory tour.

These activities enabled participating children to gain first-hand insight into their parents' daily work, while offering them an exceptional opportunity to explore the field of biotechnology. Through close interaction with the research environment, participants broadened their scientific horizons in an engaging atmosphere, effectively inspiring curiosity and strong interest in life sciences.



Indicator	2024	2025	Unit
Community charitable donations	68,015	41,000	RMB

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
Section C: “Comply or Explain” Provisions		
A1	<p>Emissions:</p> <p>General Disclosure</p> <p>Information on:</p> <p>(a) the policies; and</p> <p>(b) compliance with relevant laws and regulations that have a significant impact on the issuer</p> <p>relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.</p> <p><i>Note:</i> Air emissions include NO_x, SO_x, and other pollutants regulated under national laws and regulations.</p> <p>Greenhouse gases include carbon dioxide, methane, nitrous oxide, hydrofluorocarbons, perfluorocarbons and sulphur hexafluoride.</p> <p>Hazardous wastes are those defined by national regulations.</p>	<p>4.2. Energy Conservation and Emission Reduction Actions and Measures</p> <p>4.3. Waste Management</p>
KPI A1.1	The types of emissions and respective emissions data.	4.3. Waste Management
KPI A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	4.3. Waste Management
KPI A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	4.3. Waste Management
KPI A1.5	Description of emissions target(s) set and steps taken to achieve them.	4.1. Supporting the Climate Actions
KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	4.1. Supporting the Climate Actions 4.3. Waste Management



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
A2	<p>Use of Resource:</p> <p>General Disclosure</p> <p>Policies on the efficient use of resources, including energy, water and other raw materials.</p> <p><i>Note:</i> Resources may be used in production, in storage, transportation, in buildings, electronic equipment, etc.</p>	<p>4.2. Energy Conservation and Emission Reduction Actions and Measures</p> <p>4.4. Resource Management</p>
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	4.2. Energy Conservation and Emission Reduction Actions and Measures
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	4.4. Resource Management
KPI A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	4.2. Energy Conservation and Emission Reduction Actions and Measures
KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	4.4. Resource Management
KPI A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	4.4. Resource Management
A3	<p>The Environment and Natural Resources:</p> <p>General Disclosure</p> <p>Policies on minimising the issuer's significant impact on the environment and natural resources.</p>	4.2. Energy Conservation and Emission Reduction Actions and Measures
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	4.2. Energy Conservation and Emission Reduction Actions and Measures

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
B1	<p>Employment:</p> <p>General Disclosure</p> <p>Information on:</p> <p>(a) the policies; and</p> <p>(b) compliance with relevant laws and regulations that have a significant impact on the issuer</p> <p>relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.</p>	<p>5.1. Employment Compliance and Employee Benefits</p> <p>5.2. Diversity, Equality and Inclusiveness</p>
KPI B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	5.1. Employment Compliance and Employee Benefits
KPI B1.2	Employee turnover rate by gender, age group and geographical region.	5.1. Employment Compliance and Employee Benefits
B2	<p>Health and Safety:</p> <p>Information on:</p> <p>(a) the policies; and</p> <p>(b) compliance with relevant laws and regulations that have a significant impact on the issuer</p> <p>relating to providing a safe working environment and protecting employees from occupational hazards.</p>	5.3. Occupational Health and Safety
KPI B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	5.3. Occupational Health and Safety
KPI B2.2	Lost days due to work injury.	5.3. Occupational Health and Safety
KPI B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	5.3. Occupational Health and Safety



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
B3	Development and training: General Disclosure Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities. <i>Note:</i> Training refers to vocational training. It may include internal and external courses paid by the employer.	5.4. Human Capital Development
KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	5.4. Human Capital Development
KPI B3.2	The average training hours completed per employee by gender and employee category.	5.4. Human Capital Development
B4	Labour Standards: General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child or forced labour.	5.1. Employment Compliance and Employee Benefits
KPI B4.1	Description of measures to review employment practices to avoid child and forced labour.	5.1. Employment Compliance and Employee Benefits
KPI B4.2	Description of steps taken to eliminate such practices when discovered.	5.1. Employment Compliance and Employee Benefits

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
B5	<p>Supply Chain Management:</p> <p>General Disclosure</p> <p>Policies on managing environmental and social risks of the supply chain.</p>	2.6 Sustainable Supply Chain
KPI B5.1	Number of suppliers by geographical region.	2.6 Sustainable Supply Chain
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	2.6 Sustainable Supply Chain
KPI B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	2.6 Sustainable Supply Chain
KPI B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	2.6 Sustainable Supply Chain
B6	<p>Product Responsibility:</p> <p>Information on:</p> <p>(a) the policies; and</p> <p>(b) compliance with relevant laws and regulations that have a significant impact on the issuer</p> <p>relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.</p>	<p>2.3 Quality Management</p> <p>2.4 Animal Welfare and Rights</p> <p>2.5 Protection of Clients' Rights and Interests</p>
KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	2.3 Quality Management
KPI B6.2	Number of products and service related complaints received and how they are dealt with.	2.5 Protection of Clients' Rights and Interests
KPI B6.3	Description of practices relating to observing and protecting intellectual property rights.	2.2 Intellectual Property Management
KPI B6.4	Description of quality assurance process and recall procedures.	2.3 Quality Management



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
KPI B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	2.5 Protection of Clients' Rights and Interests
B7	<p>Anti-corruption:</p> <p>General Disclosure</p> <p>Information on:</p> <p>(a) the policies; and</p> <p>(b) compliance with relevant laws and regulations that have a significant impact on the issuer</p> <p>relating to bribery, extortion, fraud and money laundering.</p>	1.2 Business Ethics and Anti-corruption
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	1.2 Business Ethics and Anti-corruption
KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	1.2 Business Ethics and Anti-corruption
KPI B7.3	Description of anti-corruption training provided to directors and staff.	1.2 Business Ethics and Anti-corruption
B8	<p>Community Investment:</p> <p>Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.</p>	5.5. Community Responsibility and Contribution
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	5.5. Community Responsibility and Contribution
KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	5.5. Community Responsibility and Contribution

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
Section D: Climate-related Disclosures		
Governance	<p>19(a) An issuer shall disclose information about: the governance body(s) (which can include a board, committee or equivalent body charged with governance) or individual(s) responsible for oversight of climate-related risks and opportunities. Specifically, the issuer shall identify that body(s) or individual(s) and disclose information about:</p> <ul style="list-style-type: none"> (i) how the body(s) or individual(s) determines whether appropriate skills and competencies are available or will be developed to oversee strategies designed to respond to climate-related risks and opportunities; (ii) how and how often the body(s) or individual(s) is informed about climate-related risks and opportunities; (iii) how the body(s) or individual(s) takes into account climate-related risks and opportunities when overseeing the issuer’s strategy, its decisions on major transactions, and its risk management processes and related policies, including whether the body(s) or individual(s) has considered trade-offs associated with those risks and opportunities; and (iv) how the body(s) or individual(s) oversees the setting of, and monitors progress towards, targets related to climate-related risks and opportunities, including whether and how related performance metrics are included in remuneration policies. 	4.1. Supporting the Climate Actions – Climate Governance



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	<p>19(b) management’s role in the governance processes, controls and procedures used to monitor, manage and oversee climate-related risks and opportunities, including information about:</p> <ul style="list-style-type: none"> (i) whether the role is delegated to a specific management-level position or management-level committee and how oversight is exercised over that position or committee; and (ii) whether management uses controls and procedures to support the oversight of climate-related risks and opportunities and, if so, how these controls and procedures are integrated with other internal functions. 	4.1. Supporting the Climate Actions – Climate Governance
Strategy	<p>20. An issuer shall disclose information to enable an understanding of climate-related risks and opportunities that could reasonably be expected to affect the issuer’s cash flows, its access to finance or cost of capital over the short, medium or long term. Specifically, the issuer shall:</p> <ul style="list-style-type: none"> (a) describe climate-related risks and opportunities that could reasonably be expected to affect the issuer’s cash flows, its access to finance or cost of capital over the short, medium or long term; (b) explain, for each climate-related risk the issuer has identified, whether the issuer considers the risk to be a climate-related physical risk or climate-related transition risk; (c) specify, for each climate-related risk and opportunity the issuer has identified, over which time horizons – short, medium or long term – the effects of each climate-related risk and opportunity could reasonably be expected to occur; and (d) explain how the issuer defines “short term”, “medium term” and “long term” and how these definitions are linked to the planning horizons used by the issuer for strategic decision-making. 	4.1. Supporting the Climate Actions – Climate Strategy

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	<p>21. An issuer shall disclose information that enables an understanding of the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain. Specifically, the issuer shall disclose:</p> <p>(a) a description of the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain; and</p> <p>(b) a description of where in the issuer's business model and value chain climate-related risks and opportunities are concentrated (for example, geographical areas, facilities and types of assets).</p>	4.1. Supporting the Climate Actions – Climate Strategy
	<p>22(a) An issuer shall disclose information that enables an understanding of the effects of climate-related risks and opportunities on its strategy and decision-making. Specifically, the issuer shall disclose information about how the issuer has responded to, and plans to respond to, climate-related risks and opportunities in its strategy and decision-making, including how the issuer plans to achieve any climate-related targets it has set and any targets it is required to meet by law or regulation. Specifically, the issuer shall disclose information about:</p> <p>(i) current and anticipated changes to the issuer's business model, including its resource allocation, to address climate-related risks and opportunities;</p> <p>(ii) current and anticipated adaptation and mitigation efforts (whether direct or indirect);</p> <p>(iii) any climate-related transition plan the issuer has (including information about key assumptions used in developing its transition plan, and dependencies on which the issuer's transition plan relies), or an appropriate negative statement where the issuer does not have a climate-related transition plan.</p> <p>(iv) How the issuer plans to achieve any climate-related targets (including any greenhouse gas emissions targets (if any)), described in accordance with paragraphs 37 to 40.</p>	4.1. Supporting the Climate Actions – Climate Strategy



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	22(b) information about how the issuer is resourcing, and plans to resource, the activities disclosed in accordance with paragraph 22(a).	4.1. Supporting the Climate Actions – Climate Strategy
	23. An issuer shall disclose information about the progress of plans disclosed in previous reporting periods in accordance with paragraph 22(a).	4.1. Supporting the Climate Actions – Climate Strategy
	24. An issuer shall disclose qualitative and quantitative information about:	Qualitative information:
	(a) how climate-related risks and opportunities have affected its financial position, financial performance and cash flows for the reporting period; and	4.1. Supporting the Climate Actions – Climate Strategy
	(b) the climate-related risks and opportunities identified in paragraph 24(a) for which there is a significant risk of a material adjustment within the next annual reporting period to the carrying amounts of assets and liabilities reported in the related financial statements.	Quantitative information: Adopt financial impact relief
	25(a) The issuer shall provide qualitative and quantitative disclosures about how the issuer expects its financial position to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities, taking into consideration:	Qualitative information: 4.1. Supporting the Climate Actions – Climate Strategy
	(i) its investment and disposal plans; and	Quantitative information:
	(ii) its planned sources of funding to implement its strategy.	Adopt financial impact relief
	25(b) The issuer shall provide qualitative and quantitative disclosures about: how the issuer expects its financial performance and cash flows to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities.	Adopt financial impact relief

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	<p>26(a) An issuer shall disclose information that enables an understanding of the resilience of the issuer’s strategy and business model to climate-related changes, developments and uncertainties, taking into consideration the issuer’s identified climate-related risks and opportunities. An issuer shall use climate-related scenario analysis to assess its climate resilience using an approach that is commensurate with an issuer’s circumstances. In providing quantitative information, the issuer may disclose a single amount or a range. Specifically, the issuer shall disclose the issuer’s assessment of its climate resilience as at the reporting date, which shall enable an understanding of:</p> <ul style="list-style-type: none"> (i) the implications, if any, of the issuer’s assessment for its strategy and business model, including how the issuer would need to respond to the effects identified in the climate-related scenario analysis; (ii) the significant areas of uncertainty considered in the issuer’s assessment of its climate resilience; and (iii) the issuer’s capacity to adjust, or adapt its strategy and business model to climate change over the short, medium or long term. 	Adopt reasonable data relief



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	<p>26(b) An issuer shall disclose information about how and when the climate-related scenario analysis was carried out, including:</p> <p>(i) information about the inputs used, including:</p> <ol style="list-style-type: none">1) which climate-related scenarios the issuer used for the analysis and the sources of such scenarios;2) whether the analysis included a diverse range of climate-related scenarios;3) whether the climate-related scenarios used for the analysis are associated with climate-related transition risks or climate-related physical risks;4) whether the issuer used, among its scenarios, a climate-related scenario aligned with the latest international agreement on climate change;5) why the issuer decided that its chosen climate-related scenarios are relevant to assessing its resilience to climate-related changes, developments or uncertainties;6) time horizons the issuer used in the analysis; and7) what scope of operations the issuer used in the analysis (for example, the operation, locations and business units used in the analysis);8) the key assumptions the issuer made in the analysis; and9) the reporting period in which the climate-related scenario analysis was carried out.	Adopt reasonable data relief

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
Risk Management	<p>27(a) An issuer shall disclose information about the processes and related policies it uses to identify, assess, prioritise and monitor climate-related risks, including information about:</p> <ul style="list-style-type: none"> (i) the inputs and parameters the issuer uses (for example, information about data sources and the scope of operations covered in the processes); (ii) whether and how the issuer uses climate-related scenario analysis to inform its identification of climate-related risks; (iii) how the issuer assesses the nature, likelihood and magnitude of the effects of those risks (for example, whether the issuer considers qualitative factors, quantitative thresholds or other criteria); (iv) whether and how the issuer prioritises climate-related risks relative to other types of risks; (v) how the issuer monitors climate-related risks; and (vi) whether and how the issuer has changed the processes it uses compared with the previous reporting period. 	<p>4.1. Supporting the Climate Actions – Climate Risk Management</p>



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	27(b) The processes the issuer uses to identify, assess, prioritise and monitor climate-related opportunities (including information about whether and how the issuer uses climate-related scenario analysis to inform its identification of climate-related opportunities).	4.1. Supporting the Climate Actions – Climate Risk Management
	27(c) The extent to which, and how, the processes for identifying, assessing, prioritising and monitoring climate-related risks and opportunities are integrated into and inform the issuer’s overall risk management process.	4.1. Supporting the Climate Actions – Climate Risk Management
Metrics and Targets	28. An issuer shall disclose its absolute gross greenhouse gas emissions generated during the reporting period, expressed as metric tons of CO ₂ equivalent, classified as: (a) Scope 1 greenhouse gas emissions; (b) Scope 2 greenhouse gas emissions; and (c) Scope 3 greenhouse gas emissions.	4.2. Energy Conservation and Emission Reduction Actions and Measures

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	<p>29. An issuer shall:</p> <p>(a) measure its greenhouse gas emissions in accordance with the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (2004) unless required by a jurisdictional authority or another exchange on which the issuer is listed to use a different method for measuring greenhouse gas emissions;</p> <p>(b) disclose the approach it uses to measure its greenhouse gas emissions including: (i) the measurement approach, inputs and assumptions the issuer uses to measure its greenhouse gas emissions; (ii) the reason why the issuer has chosen the measurement approach, inputs and assumptions it uses to measure its greenhouse gas emissions; and (iii) any changes the issuer made to the measurement approach, inputs and assumptions during the reporting period and the reasons for those changes;</p> <p>(c) for Scope 2 greenhouse gas emissions disclosed in accordance with paragraph 28(b), disclose its location-based Scope 2 greenhouse gas emissions, and provide information about any contractual instruments that is necessary to enable an understanding of the issuer's Scope 2 greenhouse gas emissions; and</p> <p>(d) for Scope 3 greenhouse gas emissions disclosed in accordance with paragraph 28(c), disclose the categories included within the issuer's measure of Scope 3 greenhouse gas emissions, in accordance with the Scope 3 categories described in the Greenhouse Gas Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard (2011).</p>	<p>4.2. Energy Conservation and Emission Reduction Actions and Measures</p>



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	30. An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related transition risks.	Adopt reasonable data relief
	31. An issuer shall disclose the amount and percentage of assets or business activities vulnerable to climate-related physical risks.	Adopt reasonable data relief
	32. An issuer shall disclose the amount and percentage of assets or business activities aligned with climate-related opportunities.	Adopt reasonable data relief
	33. An issuer shall disclose the amount of capital expenditure, financing or investment deployed towards climate-related risks and opportunities.	4.2. Energy Conservation and Emission Reduction Actions and Measures
	34. An issuer shall disclose: (a) an explanation of whether and how the issuer is applying a carbon price in decision-making (for example, investment decisions, transfer pricing, and scenario analysis); and (b) the price of each metric tonne of greenhouse gas emissions the issuer uses to assess the costs of its greenhouse gas emissions; or an appropriate negative statement confirming that the issuer does not apply carbon pricing in its decision-making.	4.1. Supporting the Climate Actions – Climate Metrics and Targets

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	35. An issuer shall disclose whether and how climate-related considerations are factored into remuneration policy, or an appropriate negative statement. This may form part of the disclosure under paragraph 19(a)(iv).	4.1. Supporting the Climate Actions – Climate Metrics and Targets
	36. An issuer is encouraged to disclose industry-based metrics that are associated with one or more particular business models, activities or other common features that characterise participation in an industry. In determining the industry-based metrics that the issuer discloses, an issuer is encouraged to refer to and consider the applicability of the industry-based metrics associated with disclosure topics described in the IFRS S2 Industry-based Guidance on implementing Climate-related Disclosures and other industry-based disclosure requirements prescribed under other international ESG reporting frameworks.	4.1. Supporting the Climate Actions – Climate Metrics and Targets



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	<p>37. An issuer shall disclose (a) the qualitative and quantitative climate-related targets the issuer has set to monitor progress towards achieving its strategic goals; and (b) any targets the issuer is required to meet by law or regulation, including any greenhouse gas emissions targets. For each target, the issuer shall disclose:</p> <ul style="list-style-type: none">(a) the metric used to set the target;(b) the objective of the target (for example, mitigation, adaptation or conformance with science-based initiatives);(c) the part of the issuer to which the target applies (for example, whether the target applies to the issuer in its entirety or only a part of the issuer, such as a specific business unit or geographic region);(d) the period over which the target applies;(e) the base period from which progress is measured;(f) milestones or interim targets (if any);(g) if the target is quantitative, whether the target is an absolute target or an intensity target; and(h) how the latest international agreement on climate change, including jurisdictional commitments that arise from that agreement, has informed the target.	<p>4.1. Supporting the Climate Actions – Climate Metrics and Targets</p>

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	<p>38. An issuer shall disclose information about its approach to setting and reviewing each target, and how it monitors progress against each target, including:</p> <ul style="list-style-type: none"> (a) whether the target and the methodology for setting the target has been validated by a third party; (b) the issuer’s processes for reviewing the target; (c) the metrics used to monitor progress towards reaching the target; and (d) any revisions to the target and an explanation for those revisions. 	4.1. Supporting the Climate Actions – Climate Metrics and Targets
	<p>39. An issuer shall disclose information about its performance against each climate-related target and an analysis of trends or changes in the issuer’s performance.</p>	4.1. Supporting the Climate Actions – Climate Metrics and Targets



APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	<p>40. For each greenhouse gas emissions target disclosed in accordance with paragraphs 37 to 39, an issuer shall disclose:</p> <ul style="list-style-type: none">(a) which greenhouse gases are covered by the target;(b) whether Scope 1, Scope 2 or Scope 3 greenhouse gas emissions are covered by the target;(c) whether the target is a gross greenhouse gas emissions target or a net greenhouse gas emissions target. If the issuer discloses a net greenhouse gas emissions target, the issuer is also required to separately disclose its associated gross greenhouse gas emissions target;(d) whether the target was derived using a sectoral decarbonisation approach; and(e) the issuer's planned use of carbon credits to offset greenhouse gas emissions to achieve any net greenhouse gas emissions target. In explaining its planned use of carbon credits, the issuer shall disclose: (i) the extent to which, and how, achieving any net greenhouse gas emissions target relies on the use of carbon credits; (ii) which third-party scheme(s) will verify or certify the carbon credits; (iii) the type of carbon credit, including whether the underlying offset will be nature-based or based on technological carbon removals, and whether the underlying offset is achieved through carbon reduction or removal; and (iv) any other factors necessary to enable an understanding of the credibility and integrity of the carbon credits the issuer plans to use (for example, assumptions regarding the permanence of the carbon offset).	<p>4.1. Supporting the Climate Actions – Climate Metrics and Targets</p>

APPENDIX: HKEX ESG REPORTING CODE CONTENT INDEX

Aspect	Disclosure Requirements	Content Index
	41. In preparing disclosures to meet the requirements in paragraphs 21 to 26 and 37 to 38, an issuer shall refer to and consider the applicability of cross-industry metrics (see paragraphs 28 to 35) and (ii) industry-based metrics (see paragraph 36).	4.2. Energy Conservation and Emission Reduction Actions and Measures